Biochemical aspects of ALA-PDT : basic mechanisms and optimization for the treatment of Barrett's oesophagus by Hinnen, P. (Petra)
Biochemical Aspects of ALA-PDT 
Basic mechanisms and optimization for 
the treatment of Barrett's oesophagus 
Petra Hinnen 
Cover design: porphyrin structures (with help of Pascal and Kiara) 
The financial support of AstraZeneca for the pUblication of this thesis 
is gratefully acknowledged. 
Printed by Optima Grafische Communicatie, Rotterdam 
Biochemical Aspects of AlA-PDT 
Basic mechanisms and optimization for 
the treatment of Barrett's oesophagus 
Biochemische Aspecten van ALA-PDT 
Basale mechanismen en optimalisering voor 
de behandeling van Barrett slokdarm 
PROEFSCHRIFT 
Ter verkrijging van de graad van dodor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de Redor Magnificus 
Prof. dr. ir. J.H. van Semmel 
en volgens het besluit van het College voor Promoties. 
De openbare verdediging zal plaatsvinden op 
21 februari 2001 om 13.45 uur 
door 
Petra Hinnen 
geboren te Coevorden 
Promotiecommissie 
Promotor : Prof JHP Wilson 
Copromotoren : Dr FWM de Rooij 
: Dr PD Siersema 
Overige leden : Prof dr EMH Mathus - Vliegen 
: Prof dr HG van Eijk 
: Prof dr HW Tilanus 
Voor pappa, mamma en Yvonne 

CONTENTS 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Introduction 
IKR bulletin 1996;20(3):30-34 
Ned Tijdsch Geneesk 1998;142(43):2341-2345 
Biochemical basis of ALA-induced PPIX accumulation: 
a study in patients with (pre)malignant lesions of the oesophagus 
British Journal of Cancer 1998;78(5):679-682 
Acrylate yellow filters in operating lights 
protect against photosensitization tissue damage. 
British Journal of Surgery 2000;87:231-235 
Porphyrin biosynthesis in human Barrett's oesophagus and 
adenocarcinoma after ingestion of 5-aminolaevulinic acid 
British Journal of Cancer 2000;83(4):539-543 
Timing of 5-aminolaevulinic acid-induced photodynamic therapy 
for the treatment of patients with Barrett's oesophagus. 
Submitted 
Ferrochelatase activity inhibition by 5-aminolaevulinic 
acid-induced photodynamic therapy. 
Submitted 
A two-phase illumination scheme in ALA-PDT: 
improvement of the clinical outcome? 
Submitted 
General Discussion 
Summary 
Samenvatting 
Addendum 
Dankwoord 
Curriculum Vitae 
List of Publications 
List of Abbreviations 
1 
25 
37 
49 
65 
81 
95 
109 
121 
129 
137 

2 3 4 5 6 7 8 9 10 
Introduction 
..• ~ 
In part adapted from: 
IKR bulletin 1996; 20(3}: 30-34. Fotodynamische therapie bij Barrett epitheel en ado-
nocarcinoom van de oesophagus. Hinnen et al. 
Ned Tijdscn Geneesk 1998; 142(43}: 2341-2345. Endoscopische behandeling van 
Barretl-oesofagus. Hinnen et al. 
11 

Introduction 
I. BARRETT'S OESOPHAGUS AND ADENOCARCINOMA OF THE OESOPHAGUS 
From the late 1970s, the incidence of adenocarcinoma of the oesophagus has increased 
more rapidly than that of any other cancer in the western world (Blot et ai., 1991). 
Adenocarcinoma of the oesophagus usually occurs in patients who have Barrett's oesophagus 
(Cameron et ai., 1995). Barrett's oesophagus is a complication of chronic 
gastro(duodeno)oesophageal reflux (Hamilton, 1985). 
The true prevalence of Barrett's oesophagus is unknown. In patients with long-standing 
gastro-oesophageal reflux disease the prevalence of Barrett's oesophagus is at least 10% 
(Winters et ai., 1987). However, an autopsy study performed by Cameron et ai. suggested 
that for every patient discovered during investigation for reflux symptoms there are 20 
patients in the general population with undiagnosed Barrett's oesophagus (Cameron et 
al., 1990). Prospective studies reported a 30-125 times higher risk of developing 
adenocarcinoma in patients with Barrett's oesophagus than in the general population 
(Cameron et ai., 1985; Drewitz et al., 1997; Hameeteman et ai., 1989; Spechler et ai., 
1984; van der Veen et al., 1989). Barrett's oesophagus is therefore considered to be a 
relatively common lesion that has a significant malignant potential. 
As a consequence of long-term reflux of acid, pepsin and bile, the normal squamous-lined 
oesophagus is injured (Attwood et a1., 1993). Multipotential stem cells in an eroded or ulcerated 
area may differentiate into three types of metaplastic epithelium; a gastric fundic type, a 
junctional type and an intestinal type. Barrett's oesophagus is a histological diagnosis. At 
endoscopy it can be recognized as a deep-red mucosa that contrasts sharply with the pale-
pink adjacent squamous epithelium, but the diagnosis is not confirmed until intestinal 
metaplasia has been revealed by histologic examination (Paull et ai., 1976). Intestinal 
metaplasia is characterized by goblet cells and this particular epithelium carries the highest 
risk of developing adenocarcinoma (Hameeteman et ai., 1989). 
Metaplasia in itself is benign, however it has the potential to undergo changes. Barrett's 
oesophagus can lead to the development of an adenocarcinoma through a multistep process 
of progression from metaplasia to low-grade dysplasia, high-grade dysplasia and ultimately 
to invasive cancer (Haggitt, 1994; Hameeteman et al., 1989; Hamilton and Smith, 1987; 
Miros et al., 1991). The risk of progression of Barrett's oesophagus into an 
adenocarcinoma seems to be related to the length of the columnar lined segment and 
the presence of ulcers (lftikhar et ai., 1992; Komorowski et a1., 1996). Alcohol consumption 
and smoking are also associated with the development of adenocarcinoma in Barrett's 
oesophagus (Gray et ai., 1993). 
Although the sequence through which an adenocarcinoma develops within Barrett's 
oesophagus is known, little is known about the natural history of dysplasia in Barrett's 
oesophagus. Two prospective studies in which patients with high-grade dysplasia were 
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followed endoscopically for several months reported regression of high-grade dysplasia 
and state that high-grade dysplasia does not always progress to carcinoma (Levine et al., 
1996; Schnell et al., 1996). It is presently not known which patient will develop an 
adenocarcinoma and at what time interval. Effort has been made to find biochemical markers 
of neoplastic progression, such as p53 expression, however these markers are under research 
(Ellis and Loda, 1997; Ireland et al., 1997). In clinical practice, high-grade dysplasia within 
Barrett's epithelium remains the best clinical predictor of adenocarcinoma. 
The treatment of Barrett's oesophagus depends in part on the existence and grade of 
dysplasia. In most patients reflux symptoms are controlled by anti-reflux therapy, either 
medical (proton pump inhibitors) or surgical (Nissen fundoplication) (Ortiz et al., 1996; 
Sampliner, 1994). Although reflux is considered the major metaplasia-induCing factor, in 
all but one study (Peters et al., 1999) reducing acid exposure of the Barrett's segment 
was found to influence neither the length nor the grade of dysplasia of Barrett's oesophagus 
(Ortiz et al., 1996; Sagar et al., 1995; Sampliner, 1994). If surveillance is considered, 
patients with Barrett's oesophagus without dysplasia may undergo endoscopies every 2 
years. Patients with low-grade dysplasia may undergo regular endoscopies every 6 to 12 
months. The treatment of patients with high-grade dysplasia in Barrett's oesophagus, however, 
is still controversial. Some advocate an intensive endoscopic surveillance biopsy protocol 
(every 3 to 6 months), being convinced that multiple biopsies can differentiate high-grade 
dysplasia from early cancer (Levine et al., 1993), while others advocate an oesophagectomy 
as multiple biopsies do not exclude the presence of adenocarcinoma due to sampling errors 
and difficulties in differentiating between high-grade dysplasia and (early) adenocarcinoma 
can be difficult (Cameron and Carpenter, 1997; Edwards et al., 1996; Heitmiller et al., 
1996; Peters et al., 1994; Rusch et al., 1994). To date, the majority of patients with high-
grade dysplasia undergo a prophylactic oesophagectomy. Considering the limited information 
about the natural history of high-grade dysplasia and lack of clinically useful objective 
markers for neoplastic progression, it is presently not possible to identify patients who 
can be followed by endoscopic surveillance and patients who need immediate resection. 
As a consequence, a large number of patients with high-grade dysplasia undergo a mutilating 
operation with substantial morbidity and mortality to prevent progression that might in 
some patients never occur (Ferguson and Naunheim, 1997; Heitmiller et al., 1996; Provenzale 
et al., 1994). 
A non-invasive endoscopic ablative therapy could be an alternative to surgical resection, 
in patients with low or high-grade dysplasia and also in patients with a high surgical risk 
or for those who are averse to surgery. The conversion of intestinal metaplasia into normal 
squamous epithelium to abolish the risk of adenocarcinoma is an appealing concept. 
Endoscopic ablative therapies that are currently under investigation are photodynamic therapy 
(Barr et al., 1996; Overholt et al., 1999), multipolar electrocoagulation (Sharma et al., 
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1999), argon plasma beam coagulation (van Laethem et al., 1998), KTP laser coagulation 
(Barham et aI., 1997), Nd:Yag laser coagulation (Luman et al., 1996) and endoscopic mucosal 
resection (Ell et al., 2000) all in combination with acid suppression by proton pump inhibitors 
to allow squamous regeneration in a neutral environment (Berenson et al., 1993). 
We have been interested in the possibilities of using 5-aminolaevulinic acid in photodynamic 
therapy (ALA-PDT) of Barrett's oesophagus. This thesis presents five studies that focus on 
the basic mechanisms of ALA-PDT with the aim of improving therapy. 
II. PHOTODYNAMIC THERAPY 
a. history 
Photodynamic therapy (PDT) is an experimental treatment for localized premalignant and 
malignant tumours. PDT is based on the accumulation of photosensitizers in these tissues 
after intravenous or oral administration. Subsequent illumination with a specific wavelength 
induces a photochemical reaction between light and the photosensitizing substance. With 
a combination of photosensitizer dose, time interval between administration and illumination 
and light distribution, it may be possible to destroy tumours without damaging normal 
adjacent tissue. 
The principle of light activation of photosensitive substances is not new. In 1898, McCall-
Anderson discovered the photosensitizing ability of porphyrin molecules as his patients 
with skin photosenstivity were found to have haematoporphyrin (Hp) in their pigmented 
urine (McCall-Anderson, 1898). Early in the 19th century Raab reported the killing of 
protozoa after the photochemical interaction between light and acridine orange (Raab, 
1900). In 1903, Von Tappeiner and Jesionek treated skin carcinomas by topical application 
of eosin and illumination (Tappeiner von and Jesionek, 1903). Meyer-Betz injected himself 
with Hp and described the resulting skin photosensitivity with severe skin edema and 
erythema lasting for more than two months (Meyer-Betz, 1913). In 1940, Hp was discovered 
to have tumour-localizing properties. Lipson et al. (Lipson et al., 1961) discovered that a 
derivative of Hp had even better tumour localizing properties than Hp itself and 
haematoporphyrin derivative (HpD) was used in most studies until Dougherty et a/. isolated 
the active fraction of HpD, porfimer sodium (commercially known as Photofrin®) in 1984 
(Dougherty et al., 1984). To date Photofrin® is the only drug approved for clinical application 
of PDT. 
In 1956, Berlin et al. were the first to administer 5-aminolaevulinic acid (ALA) to animals 
and humans (to study haem and billirubin synthesis). Volunteers were subjected to light 
and skin photosensitivity lasting for 2 days was described (Berlin et al., 1956). The first 
clinical applications of ALA-PDT were studied by Kennedy et al. in 1990. They applied 
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ALA to skin tumours and successfully treated them with light (Kennedy et al., 1990). A 
large number of studies have been performed in the 1980's and 1990's investigating the 
pharmacokinetics of ALA and ALA-induced protoporphyrin IX (PPIX) in tumour cell models, 
animals and humans ((Peng et al., 1997; Peng et al., 1997), reviews). 
To date, many different premalignant and malignant tumours have been treated with PDT, 
including skin cancer (Fritsch et aI., 1998), bladder cancer (Kriegmair et al., 1996; Riesenberg 
et al., 1996), lung cancer (Kato, 1998), brain tumours (Popovic et al., 1995), gynaecological 
tumours (Gannon and Brown, 1999) and tumours in the gastro-intestinal tract (Gossner 
et al., 1998; Mlkvy et ai" 1995; Tan et al., 1999). Another potential application of PDT 
is intra-operative PDT after tumour resection (Abulafi et al., 1997; van Hillegersberg et 
ai" 1995), 
triplet state 
substrate 
fluorescence 
~ singlet state ~ ~ li~OrP.tio~020x;d;zed 
.----...;:..,/ / substrate 
ground state ~ 
FIGURE 1 Photochemical reaction type II, O2 = oxygen, 102 = singlet oxygen 
b. photochemical reactions 
ALA-PDT is based on the intracellular accumulation of ALA-induced protoporphyrin IX (PPIX), 
a photosensitizing substance that can produce tissue destruction after absorbing light of 
an appropriate wavelength. The cytotoxic effect of PDT is the result of photo-oxidative 
reactions. The first step of these reactions is absorption of light energy by PPIX (ground 
state) to produce an excited state (singlet state) (FIGURE 1, after (van Hillegersberg et al., 
1994». From this singlet state the photosensitizer can decay back to the ground state 
and emit light in the form of fluorescence. For the photodynamic effect, however, the 
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photosensitizer should undergo intersystem crossing to the excited triplet state of the 
molecule. Two competing reactions of the excited sensitizer can occur (Foote, 1991). Triplet 
state molecules can (a) react directly either with substrate or solvent by hydrogen atom 
or electron transfer to form radicals and radical ions, which after interaction with oxygen 
can produce oxygenated products (Type I reaction), or, (b) it can transfer its energy to 
oxygen directly to form highly reactive singlet oxygen (oxygen radicals, '0" Type II reaction). 
The two reaction types can occur simultaneously but singlet oxygen is probably the most 
important cytotoxic agent responsible for the destruction of tissue (Weishaupt et aI" 1976). 
The singlet oxygen reacts in turn with amino acids, unsaturated fatty acids and nucleic 
acids at its site of generation, because of the limited diffusion length and short lifetime 
ofthese radicals (Moan, 1990). This results in damage to cell function and structure. From 
the above it is evident that PDT requires the presence of three components for its action, 
namely: a photosensitizer, light and oxygen. 
c. photosensitizer 
An ideal photosensitizer (Bonnett and Berenbaum, 1989) should: 
(1) have a low systemic toxicity, 
(2) have minimal dark toxicity, 
(3) preferentially localize in (pre)malignant cells, 
(4) be rapidly cleared from normal tissue, 
(5) absorb wavelengths in the red or nearby infrared region of the light spectrum as tissue 
penetration is deeper than in the blue region, 
(6) have a high triplet state quantum yield, e,g, high probability of triplet state formation 
per absorbed light energy quantum and 
(7) be a chemically well-defined stable substance. 
To date no such photosensitizer has been found, So far, the clinically most frequently 
studied photosensitizer for the treatment of Barrett's oesophagus is porfimer sodium 
(Photofrin®) (Overholt et aI" 1999), Photofrin® is a mixture of non-metallic oligomeriC 
porphyrins linked mainly through ether bounds and only meets criteria 2 and 5 of the 
ideal photosensitizer criteria (Dougherty et aI" 1984), A major disadvantage of Photofrin® 
is the limited selectivity with regard to uptake and retention by tumour versus normal 
cells (Orenstein et al., 1996). All tissues accumulate porphyrins to some extent, however, 
tissues remote from light are safe from light-induced damage. Skin cells also accumulate 
porphyrins and a serious side effect of Photofrin® is continued light photosensitivity of 
exposed skin for several weeks or months after treatment (Dougherty et aI" 1990), Another 
drawback of this photosensitizer, in particular for the treatment of a superficial lesion like 
Barrett's oesophagus, is stricture formation in up to 34% of the patients due to deep 
oesophageal wall damage (Overholt et al., 1999). 
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In this thesis 5-aminolaevulinic acid (ALA) is studied. The difference with Photofrin® is 
that the photosensitizer - protoporphyrin IX (PPIX)- is synthesized in situ from ALA. ALA 
is a naturally occurring intermediate in the haem biosynthetic pathway. Production of PPIX 
will be discussed in the next section of this chapter. Several advantages (meeting criteria 
1,2,4,5,7 ofthe ideal photosensitizer criteria) using ALA-induced PPIX photosensitization 
have been reported. 
First, PPIX is rapidly eliminated from the body and hence the risk of skin photosensitivity 
is limited to 1-2 days (Berlin et al., 1956; Kennedy and Pottier, 1992). 
Secondly, in several studies it has been found that epithelial surfaces as epidermis, buccal 
mucosa, gastro-intestinal tract mucosa, respiratory tract mucosa, vaginal mucosa and glands 
or organs in continuity with such surfaces such as liver, sebaceous- and salivary glands 
may accumulate PPIX. However, tissues of mesodermal origin like muscle, connective tissue, 
cartilage did not show significant PPIX accumulation after ALA administration (Bedwell 
et al., 1992; Kennedy and Pottier, 1992; Loh et al., 1993; Loh et al., 1993; Peng et al., 
1997). ALA-PDT treatment of Barrett's oesophagus would cause superficial damage to 
the oesophageal wall with much less risk of stricture formation (Gossner et al., 1998). 
Thirdly, ALA appears to offer better selectivity in terms of photosensitizer accumulation 
between tumour and normal tissues. Several in vivo animal studies have shown semi-selective 
ALA-induced PPIX accumulation in tumours compared to normal tissue (Bedwell et al., 
1992; Berlin et al., 1956; Regula et al., 1995; Regula et al., 1994; van Hillegersberg et 
al., 1995). However in human studies this has not been convincingly demonstrated and 
this is still a controversial matter (Barr et al., 1996; Tan et al., 1999). 
Lastly, ALA can be given orally as well as applied locally (in creams, to treat skin lesions), 
providing an acceptable and convenient route of administration, which may be an advantage 
when treating patients on an outpatient basis (Gossner et al., 1998; Loh et al., 1993). 
d. excitation light 
As an optimal interaction between the photosensitizer and light is one of the premisses 
for an effect of PDT, it is important that light of a specific wavelength is used. The choice 
of the wavelength is determined by the absorption spectrum of the photosensitizer. Porphyrins 
are known for their strong absorption of UV light (the Soret band). The absorption capacity 
of 4 additional absorption bands (between 500 nm to 650 nm) is less intense (Bonnett 
and Berenbaum, 1989). As the penetration of light in tissues increases at higher wavelengths 
(FIGURE 2) (Wilson et al., 1985), the weakest absorption band at about 630 nm is currently 
used for most clinical applications of ALA-PDT (Barr et al., 1996; Grant et al., 1993; Regula 
et aI., 1995). By increasing the intensity in this wavelength the photodamage can be achieved. 
Currently a dye laser pumped by a KTP laser (532 nm, Potassium Titanium Phosphate) 
is most commonly used. Advantages of the use of laser light for PDT are the well defined 
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wavelengths that makes it possible to match with the excitation wavelength of the 
photosensitizer and the possibility of coupling laser light into optical fibers. 
Depending on the area to be treated, various forms of light delivery systems have been 
constructed. For use in the oesophagus cylindrical light diffusers in a centering balloon system 
are used (Gossner et al., 1999; Overholt et al., 1996). 
10 
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FIGURE 2 Absorption spectrum of PPIX (thin line) and the tissue penetration of various 
wavelengths. Arbitrary absorption units (%), 100% at 400 nm. 
III. HAEM BIOSYNTHESIS 
a. without exogenous ALA administration 
Haem biosynthesis is essential for every cell and requires eight molecules of glycine and 
eight molecules of succinyl eoA for each molecule of haem (FIGURE 3). Haem is the prosthetiC 
group for a number of haemoproteins. These include for instance myoglobin, 
haemoglobin, mitochondrial cytochromes, microsomal P450, catalase and peroxidase. There 
9 
Chapter 1 
are eight enzymes involved in the synthesis of haem. 
The first reaction of the haem biosynthetic pathway, which is the rate-limiting step, is the 
condensation of glycine and succinyl CoA to form ALA, catalysed by the mitochondrial 
enzyme ALA-synthase (ALA-S). ALA-S appears to have one of the most rapid turn-over 
rates of the proteins in mitochondria that works far below its Km (Druyan et al., 1969). 
The short half-life of ALA-S is a suitable property for its regulatory role in haem formation. 
Control of the rate of synthesis of this enzyme by haem itself is believed to be the major 
mode of regulation of haem biosynthesis (feedback inhibition). Haem can directly inhibit 
ALA-S as well as the transcription, translation and transport of the enzyme into mitochondria 
(Hayashi et aJ.. 1972). The next step in haem biosynthesis is catalyzed by the cytosolic 
enzyme ALA-dehydratase, which catalyzes the condensation of two molecules of ALA with 
a loss of two molecules of water to form the monopyrrole porphobilinogen (PBG). 
Subsequently, the cytosolic enzyme porphobilinogen deaminase (PBG-D) joins four molecules 
of PBG in a head-to-tail fashion to generate a linear tetrapyrrole. In the absence of the 
enzyme uroporphyrinogen III synthase (URO-S), this product is released from PBG-D as 
hydroxymethylbilane, which then cyclizes to form uroporphyrinogen L In the presence of 
URO-S as well as PBG-D, the hydroxymethylbilane is rapidly transformed into 
uroporphyrinogen III (Levin, 1968). Uroporphyrinogen decarboxylase, also localized in the 
cytosol, catalyses the sequential removal of the four carboxyl groups of the acetic acid 
side chains in uroporphyrinogen to yield coproporphyrinogen (Granick and Mauzerall, 1958). 
Coproporphyrinogen oxidase, which is present in the intermembrane space of 
mitochondria removes the carboxyl group and the two hydrogens from the propionic acid 
groups of two pyrrole rings to form vinyl groups (Grandchamp et al., 1978). The reaction 
thus yields a divinyl compound, protoporphyrinogen IX. This molecule is readily oxidized 
into protoporphyrin IX (PPIX) by protoporphyrinogen IX oxidase, an enzyme located in 
the inner mitochondrial membrane (Feirrera et al., 1988). The final step of haem biosynthesis 
is the insertion of the reduced form of iron (Fe2+) into PPIX. This reaction is catalyzed by 
ferrochelatase (FC), which is located in the inner mitochondrial membrane (Jones and 
Jones, 1969). In addition to Fe2+, Zn2+ can also be incorporated in PPIX by FC, a possibility 
used in vitro for the determination of the activity of ferrochelatase. 
b. after ALA administration 
Exogenous ALA bypasses the rate-limiting step catalysed by ALA-S and the feedback inhibition 
by haem on this particular enzyme. PBG-D then becomes the rate-limiting enzyme in haem 
formation (Bishop and Desnick, 1982). Excess ALA overloads the system and induces 
accumulation of photosensitive PPIX molecules. All cells are more or less able to accumulate 
PPIX from ALA (Sardesai et al., 1964). 
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(by courtesy of Dr 5.5. Bottemley) 
Several groups, reviewed by Peng et al., have shown that porphyrins accumulate in neoplastic 
tissue after the administration of ALA (Peng et al., 1997). In general this is thought to 
occur when PBG-D activity is increased and Fe activity is decreased. Increased PBG-D activity 
relative to normal tissue has indeed consistently been found in tumours (el-Sharabasy et 
al., 1992; Navone et aI., 1990; Schoenfeld et al., 1988) as well as in rapidly dividing cells, 
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e.g. regenerating liver cells (Schoenfeld et al., 1988; Schoenfeld et al., 1987) suggesting 
that this phenomenon might be common in situations of increased cell replication. In contrast 
with the consistent studies concerning the activity of PBG-D, there seems to be a difference 
in FC activity among different tumour types (Dailey and Smith, 1984; el-Sharabasy et al., 
1992; Rubino and Rasetii, 1966; Smith, 1987; van Hillegersberg et al., 1992). Dailey and 
Smith found a decreased FC activity in the Morris hepatoma model, however they also 
pointed out that some porphyrins can act as inhibitors of Fe (Dailey and Smith, 1984). 
Smith found decreased FC activities in human skin tumours but also in normal skin tissue 
compared to those in rat liver mitochondria (Smith, 1987). EI-Sharabasy determined the 
FC activity in whole blood samples of children and adults with acute lymphoblastic leukaemia 
(ALL), non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) and found lowered activities 
of FC in patients with ALL, slightly decreased activities and increased activities of FC in 
blood of patients with NHL and HD, respectively, compared to healthy control groups 
(el-Sharabasy et al., 1992). Compared to liver, which is one ofthe main haem-synthesizing 
tissues, most tissues have low FC activities (Webber et al., 1997). The FC activity was 
found to be decreased in a colon carcinoma liver metastasis model (van Hillegersberg et 
al., 1992). From the above it is clear that the activities of PBG-D and FC are altered in 
(pre)malignant tissues depending on the type of tissue. These findings provided the biological 
rationale for the clinical use of ALA-PDT. 
IV. PHOTOBIOLOGY OF ALA-PDT 
The reaction of Singlet oxygen with target biomolecules is generally considered as the principal 
initiating pathway leading to photodynamic damage (Moan and Berg, 1991; Weishaupt 
et al., 1976). Singlet oxygen diffuses only about 20 nm in its lifetime (Moan, 1990). 
Consequently, cellular structures close to a high photosensitizer and a high oxygen 
concentration will be preferentially damaged. Hypoxia significantly reduces the synthesis 
of PPIX (Wyld et al., 1998) and together with the reduced yield of singlet oxygen, hypoxia 
diminishes the ultimate ALA-PDT effect (Georgakoudi et al., 1999). 
In most cell lines, animal models and human studies, PPIX is the main metabolite of ALA 
accumulating at its site of production in the mitochondria (Ackroyd et al., 1999; linuma 
et al., 1994; Loh et al., 1993; van den Boogert et al., 1999). Because PPIX is formed in 
mitochondria and because the range of action of oxygen radicals is very short, mitochondrial 
damage is most likely to be the major target in the cytotoxicity of ALA-PDT (iinuma et 
al., 1994; Liang et al., 1998). Other cell compartments are also damaged by ALA-PDT 
e.g. the endoplasmatic reticulum and the nuclear envelope (Malik and Lugaci, 1987). Increased 
levels of intracellular calcium and sodium as well as cellular loss of potassium have been 
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observed after ALA-PDT (Schoenfeld et al., 1994). 
The mechanism of PDT-induced cell death initially appeared to have the characteristics 
of necrosis (Henderson and Dougherty, 1992), but an apoptotic mechanism is also likely 
as specific mitochondrial damage might trigger apoptosis. Apoptosis is often described 
as "programmed cell death" whereby a sequence of events results in DNA and cellular 
fragmentation avoiding the inflammatory effects which result from necrosis (membrane 
leakage, release of Iysosomes) (Kessel and Luo, 1998; Noodt et al., 1996; Webber et al., 
1996). 
Direct cytotoxicity has been shown to be insufficient to explain the effects of ALA-PDT. 
Cells from murine tumours remaining in situ after PDT undergo necrosis, whereas those 
explanted immediately after PDT remain viable in vitro (Henderson et al., 1985). This 
suggests that local tissue factors, for instance an effect on microcirculation (oxygen supply) 
(Leveckis et al., 1995; Roberts et al., 1994) and/or the presence of neutrophils may play 
a role as well (de Vree et al., 1996). 
V. CLINICAL STUDIES 
In 1996, Barr et al. were the first to treat five patients with Barrett's oesophagus and 
high-grade dysplasia with ALA-PDT and acid suppression (Barr et al., 1996). Four to 6 
hours after the oral administration of 60 mg/kg ALA dissolved in fruit juice, the Barrett's 
segment was illuminated by laser light of 630 nm. High-grade dysplasia was eradicated 
in all patients, without recurrence after 26-44 months of endoscopic and histological follow-
up. In two cases, non-dysplastic Barrett's epithelium was found underneath regenerative 
squamous mucosa. 
Gossner and colleagues, with a design similar to Barr et al., treated 32 patients (10 high-
grade dysplasia, 22 early cancer) with ALA-PDT (Gossner et al., 1998). High-grade dysplasia 
and thin mucosal cancer ($ 2mm, 77% of all early cancers) was eradicated in all patients 
at a mean follow-up of 10 months. In two patients non.<Jysplastic Barrett's epithelium was 
detected underneath the newly formed squamous epithelium. Fifteen patients experienced 
transient nausea up to 6 hours after ALA administration and in 21 of 32 patients transient 
increases (3 days) in transaminase levels were documented. In both studies, no strictures 
or photosensitivity of the skin were reported. 
Biddlestone et al. described the histopathology of the treated Barrett's oesophagus after 
ALA-PDT in 5 patients (Biddlestone et al., 1998). Three of these cases had already been 
reported by Barr et al. in 1996. The importance of their study is that they found Barrett's 
mucosa underneath the regenerated normal squamous epithelium in all 5 cases. In two 
cases this glandular mucosa was dysplastic. The existence of Barrett's epithelium underneath 
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the newly formed squamous epithelium is also called pseudoregression of Barrett's mucosa 
and has also been described after other techniques of endoscopic ablation of Barrett's 
mucosa (Berenson et al., 1993). The importance of this finding is not yet clear, one can 
speculate that the glandular mucosa is protected by the overlying normal squamous epithelium 
from the acid environment, with a reduction in inflammation and reactive cell proliferation 
resulting in a reduced neoplastic risk. However, long-term follow-up studies are required 
to investigate the behaviour of such concealed glandular mucosa. 
From the above it is apparent that ALA-PDT has the capacity of producing mucosaJ ablation 
of Barrett's mucosa harbouring dysplasia or early adenocarcinoma. However, ALA-PDT 
needs to be improved and this requires more preclinical studies. In addition, the completeness 
and duration of response need to be prospectively evaluated before PDT becomes an accepted 
modality in the management of this disease. 
VI. PRE-CLlNICAL STUDIES FOR FURTHER OPTIMIZATION OF ALA-PDT 
For many years, studies have been performed in cell lines, animal models and humans to 
find ways to optimize the effects of ALA-PDT. The three components required for the 
action of PDT (photosensitizer, oxygen and light) have been the subject of research for 
this matter. In this section relevant studies performed during the past few years will be 
reviewed. 
The intracellular concentration of ALA-induced PPIX (van den Boogert et al., 1999) and 
the intracellular localisation of PPIX at the time of PDT (Iinuma et al., 1994; Liang et al., 
1998) seem to have an impact on the results of ALA-PDT. As a consequence, timing of 
PDT after ALA administration is important as PPIX initially accumulates in mitochondria 
but at longer time intervals it will diffuse and localize at less crucial cellular sites and/or 
will be converted into haem by that time (Steinbach et al., 1995). 
Insight was gained in the possibilities of increasing the intracellular concentration of PPIX 
and of achieving the same concentration of PPIX with lower doses of ALA. The latter 
could be achieved by intravenous injection of ALA, studied in an animal model (Loh et 
al., 1993). It was also shown that the same amount of PPIX could be induced in carcinoma 
cells for concentrations 30-150 fold lower of ALA-esters than in the presence of non-esterified 
ALA (Gaullier et al., 1997). Chelation of iron by for instance desferrioxamine has been 
shown to induce higher levels of intracellular PPIX through the inhibition of ferrochelatase, 
the enzyme responsible for conversion of PPIX into haem by the insertion of iron into 
PPIX (Berg et al., 1996; Curnow et al., 1998; Tan et al., 1997). 
From other pre-clinical studies it can be learned that optimal oxygenation of the target 
tissue has to be one of the priorities at the time of PDT. These studies have shown that 
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hypoxia significantly reduces the synthesis of PPIX (Wyld et aI., 1998) and together with 
the reduced yield of singlet oxygen, hypoxia diminishes the ultimate ALA-PDT effect 
(Georgakoudi et aI., 1999). 
The effect of adjuvant therapies such as pre-treatment with adriamycine before ALA-PDT 
(Casas et al., 1997) or concomitant laser-induced hyperthermia (liu et al., 1997) have 
been studied in mice bearing a transplantable mammary adenocarcinoma and rat liver 
tumours respectively and were shown to be synergistic to the effect of ALA-PDT. 
The wavelength (Szeimies et al., 1995), total light dose (Bays et aI., 1997) and the application 
techniques of light (Gossner et al., 1999; Overholt et al., 1996) have been studied in 
relation to the PDT effect. Of especial interest is the illumination schedule used for PDT. 
It seems, at least in cell lines and animal models, that light fractionation has a significant 
positive effect on the amount of cell death. light fractionation schemes seem to improve 
the ultimate effect, probably through recovery of vascular constriction during the dark 
period and as a result re-oxygenation of the tissues (Curnow et al., 1999). This subject is 
discussed in more detail in chapter 8, the general discussion of this thesis. 
VII. AIMS AND OUTLINE OF THIS THESIS 
ALA-PDT has physical, biochemical and clinical aspects. The aim of this thesis was to study 
the haem biosynthetic pathway before and after ALA administration and to find tools to 
manipulate haem synthesis in order to optimize ALA-PDT for patients with Barrett's 
oesophagus and superficial adenocarcinomas of the oesophagus. In this thesis, the activities 
of PBG-D and FC in different tissues are the main theme, as these activities probably play 
an important role in determining the rate of PPIX syntheSiS and its accumulation after 
ALA administration. 
The first question addressed was whether relative activities of PBG-D and FC were different 
in human Barrettts oesophagus, adenocarcinoma, normal squamous epithelium and normal 
gastric mucosa (Chapter 2) and whether the ratio between the two enzymes predicts the 
accumulation of PPIX (Chapter 4). 
Prior to starting a clinical study in patients undergOing oesophageal resection, we asked 
ourself a second question concerning the light from operating lights which could be damaging 
to other tissues besides the target tissue in patients given photosensitizing agents. This 
question was whether the use of acrylate yellow filters on operating lights could have a 
protective effect in terms of a reduction of unwanted tissue damage. This effect was studied 
in a human hepatocellular cell line and in pigs, used as a pre-clinical model (Chapter 3). 
As timing of illumination is one of the important factors in the ultimate PDT effect, the 
third question addressed was whether the pharmacokinetics of ALA and PPIX were different 
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during the first hours after ALA ingestion in normal oesophageal epithelium and Barrett's 
epithelium (Chapter 5). 
The fourth question was whether ALA-PDT affected the relative activity of the two enzymes. 
This question is of potential importance for improving PDT, as a relative suppression of 
FC induced by ALA-PDT followed by a second exposure to ALA could lead to a greater 
accumulation of the photosensitizer PPIX in the illuminated tissue. This was studied in 
Iymphoblastoid cell lines and described in Chapter 6. 
Whether a two-phase illumination scheme (light fractionation) in ALA-PDT was indeed 
more effective in terms of increased PPIX accumulation and the damaging effect of PDT 
than only one illumination was the fifth question investigated in Iymphoblastoid cell lines 
and reported in Chapter 7. 
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Summary 
Administration of 5-aminolaevulinic acid (ALA) leads to porphyrin accumulation in malig-
nant and pre-malignant tissues, and ALA is used as a prod rug in photodynamic therapy 
(PDT). To understand the mechanism of porphyrin accumulation after the administration 
of ALA and to investigate whether ALA-induced protoporphyrin IX might be a suitable 
photosensitizer in Barrett's oesophagus and adenocarcinoma, we determined the activi-
ties of porphobilinogen deaminase (PBG-D) and ferrochelatase (Fe) in various malignant 
and pre-malignant as well as in normal tissues of the human oesophagus. A PDT power 
index for ALA-induced porphyrin accumulation, the ratio of PBG-D to FC normalised for 
the normal squamous epithelium of the oesophagus, was calculated to evaluate inter-tis-
sue variation in the ability to accumulate porphyrins. In malignant and pre-malignant tis-
sue a twofold increased PBG-D activity and a marginally increased FC activity was seen 
compared to normal squamous epithelium. A significant increased PDT power index in 
Barrett's epithelium and adenocarcinoma was found. Our results suggest that, after the 
administration of ALA, porphyrins will accumulate in a greater amount in Barrett's epithe-
lium and adenocarcinoma of the oesophagus due to an imbalance between PBG-D and 
FC activities. The PDT power index here defined might be an useful indicative parameter 
to predict the susceptibility of these tissues to ALA-PDT. 
Introduction 
Heme biosynthesis (FIGURE 1) is essential to every cell and requires 8 molecules of glycine 
and 8 molecules of succinyl CoA for each molecule of heme. The first intermediate is 5-
aminolaevulinic acid (ALA); two molecules of ALA are converted to porphobilinogen, 
which is metabolized to porphyrinogen intermediates by porphobilinogen deaminase 
(PBG-D). The last step is the incorporation of iron into protoporphyrin IX (PPIX), catal-
ysed by ferrochelatase (Fe). The syntheSiS of ALA is the rate-limiting step. If exogenous 
ALA is provided, then other enzymes become rate-limiting in heme formation. 
Some cancer cells have been found to have an increased activity of PBG-D (el-Sharabasy 
et al., 1992; Navone et al., 1990,1991; Rubino & Rasetti, 1966; Schoenfeld et al., 1988a) 
and in most studies these cells have been found to have a decreased activity of FC 
(Dailey & Smith, 1984; el-Sharabasy et ai., 1992; Rubino & Rasetti, 1966; Smith, 1987; 
Van Hillegersberg et al., 1992). For such cells administration of ALA will lead to the accu-
mulation of porphyrins, especially PPIX (Anderson et aI., 1981). This provides a biologi-
cal rationale for the clinical use of ALA photodynamic therapy (ALA-PDT). 
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FIGURE 1 Haem biosynthetic pathway 
Barrett's (columnar-lined) oesophagus results from long-term gastroesophageal reflux 
(Mossberg, 1966). It is of clinical 'Importance because of its malignant potential. Barrett's 
oesophagus can lead to the development of adenocarcinoma through a multistep 
process of progression from metaplasia, to low grade dysplasia, high grade dysplasia and 
ultimately to invasive cancer (Hameeteman et al., 1989; Hamilton & Smith, 1987). High 
grade dysplasia in Barrett's oesophagus presents a difficult management problem. 
Options include endoscopic surveillance and/or esophagectomy (Cameron, 1997; Clark 
et al., 1996; Levine et al., 1993). A new non-surgical management option involves erad-
icating the dysplastic epithelium and columnar mucosa by PDT. In contrast to other pho-
tosensitisers, many of which localise in the microvasculature of all tissue layers of hollow 
organs, ALA induces much higher levels of PPIX in the mucosa compared to submucosa 
or muscularis mucosae (Loh et al., 1993). ALA-PDT has been used to treat high grade 
dysplasia in Barrett's oesophagus, resulting in necrosis of dysplastic mucosa with regen-
eration of normal squamous mucosa (Barr et aI., 1996; Gossner et al., 1995; Regula et 
aI., 1995). 
To optimize ALA-PDT for Barrett's oesophagus and early carcinoma knowledge of the 
mechanism of porphyrin accumulation in these tissues is required. We determined the 
activities of PBG-D and FC in normal tissue as well as in malignant and pre-malignant tis-
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sue of the human oesophagus. These two enzymes play an important role after the 
administration of ALA; PBG-D is in many cells the rate-limiting enzyme when exogenous 
ALA is administered and FC is the enzyme directly responsible for the conversion of PPIX 
to heme. We propose the use of a PDT power index for the inter-tissue variation in the 
ability to accumulate PPIX, in order to create a parameter which might indicate the sus-
ceptibility of tissues to ALA-PDT. 
Materials and methods 
TISSUE SAMPLES 
Between August 1996 and February 1997 tissue was obtained from 27 patients (16 
males and 11 women) undergoing an esophageal resection. The mean age was 61 years 
(43-81 years). Nine patients had a squamous cell carcinoma, 18 had an adenocarcinoma 
of the distal oesophagus and in 9 of these patients Barrett's epithelium was present 
Samples from histologically proven Barrett's mucosa, squamous cell carcinoma and ade-
nocarcinoma as well as samples from normal gastric mucosa and normal squamous 
epithelium were taken immediately after the resection. In some instances, samples could 
not be taken from Barrett's mucosa. Tissue samples were embedded in formalin, sec-
tioned, and stained with hematoxylin and eosin. The grade of tumour differentiation was 
described as well as the grade of dysplasia in Barrett's mucosa. Barrett's mucosa was clas-
sified as indefinite, low grade dysplasia (LGD) and high grade dysplasia (HGD). In addi-
tion adjacent tissue samples were frozen (-70°C) until the moment of biochemical analy-
sis. All determinations were performed in duplicate within 6 weeks of resection. Control 
experiments showed no change in activities in samples stored at -70°C for this time. This 
temperature was found to be essential; when stored at -20°C, FC activity decreased with-
in a few days, whereas the PBG-D activity remained stable for weeks. 
CHEMICALS 
The following reagents were obtained from Porphyrin Products (Logan, UT, USA): PPIX 
disodium salt, zinc PPIX and porphobilinogen (PBG). Coproporphyrin, Triton X -100 were 
purchased from Sigma Chemical Co. (St Louis, MO, USA). Tris-HCL was purchased from 
Boehringer Mannheim (Mannheim, Germany) and other chemicals were purchased from 
Merck (Darmstadt, Germany). 
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FERROCHELATASE AND PORPHOBILINOGEN DEAMINASE ASSAYS 
FC activity was measured by a modification of the method of Li et al. as described pre-
viously (Li et al., 1987; Van Hillegersberg et al., 1992). PBG-D measurements were per-
formed by a modification of the method of Wilson et al. (Wilson et al., 1986). Tissue 
samples, kept on ice, were homogenised in water (1 :5, wt/wt) using a Potter Elvehjem 
homogenizer (Kontess Glass Co., Vineland, NJ, USA). An aliquot of 50 ~I of a 200 moljL 
solution of PBG in 0.1 moljL Tris-HCL buffer, pH 8.0, were added to 50 ~I of the 
homogenate. This mixture was incubated for one hour at 37°C. The reaction was 
stopped by adding 600 ~I of Tris-HCI buffer (Tris-HCI 50 mmol/L, Trichloroacetic acid 1.5 
moljL in aqua dest.) (5:7, v:v). After 5 minutes exposure to UV light (350 nm), to con-
vert porphyrinogens to porphyrins, the samples were centrifugated for 10 minutes at 
14000 x g (Eppendorf centrifuge, Merck Nederland BV, The Netherlands), and the fluo-
rescence of the supernatant was measured at 408 nm excitation and 648 nm emission 
wavelength (Perkin Elmer LS 5B with a red sensitive photomultiplier). Values were calcu-
lated according to a standard curve of coproporphyrin III in Tris-HCI buffer (1:1, v:v). 
Results were expressed as pmol of porphyrins formed per mg protein per hour. Protein 
was determined according to the method of Lowry et al. (1951). 
THE PDT POWER INDEX 
The ratio of PBG-D to FC, introduced as the PDT power index, was calculated, with the 
enzyme activities in each tissue sample relative to the activities in normal squamous 
epithelium per individual. This index was calculated according to the formula: 
[PBG-D(tissue)/FC(tissue)] x 
[FC(squamous epithelium)/PBG-D (squamous epithelium] 
STATISTICAL ANALYSIS 
Data are expressed as means ± SD and were analysed for statistical significance using the 
Wilcoxon matched-pairs signed rank sum test. The enzyme activities of the malignant 
and pre-malignant tissues were compared to the adjacent normal tissue in the same 
patient. 
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Results 
All results are shown in TABLE 1. A twofold increase in PBG-D activity was found in 
Barrett's epithelium (p~0.018) and in adenocarcinoma of the oesophagus (p~0.001) com-
pared to normal squamous epithelium. Regarding the activity of Fe, although the mean 
values were significantly increased compared to normal squamous epithelium, this 
increase was less marked compared to the PBG-D activity increase. This resulted in a sig-
nificant increase of the PDT power index in Barrett's oesophagus (p~0.046) and adeno-
carcinoma (p~0.003) compared to the normal squamous epithelium. Of the five cases of 
Barrett's oesophagus in which the index was calculated and the grade of dysplasia deter-
mined; 4 cases were classified as LGD and 1 case as HGD. The PDT power indexes were 
0.8, 1.4, 1.4, 1.6 for LGD and 2.4 for HGD. 
TABLE 1 Enzyme activities and PDT power indexes 
PBG-D activity'" Range 
Squamous epithelium n=27 22.8 ± 7.3 (10 - 42) 
Gastric mucosa n"'27 24.9 ± 8.6 (10 - 42) 
Barrett's epithelium n=7 40.6 ± 13.7t (21 - 63) 
Adenocarcinoma n=1? 55.0 ± 19.9t (25 - 93) 
Squamous cell ca. n=9 37.6 ± 14.1t (21 - 67) 
Ferrochelatase activity'" Range 
Squamous epithelium n""24 391 ± 152 (124 - 718) 
Gastric mucosa n"24 685 ± 265t (336 - 1187) 
Barrett's epithelium n=6 437 ± 203t (176 - 726) 
Adenocarcinoma n"'16 582 ± 220t (230 - 1048) 
Squamous cell ca. n=? 558 ± 332 (251 - 1263) 
PDT power index Range 
Squamous epithelium n=24 1.0 
Gastric mucosa n=24 0.7 ± 0.2t (0.3 - 1.1) 
Barrett's epithelium n=-6 1.8 ± 0.8t (0.8 - 3.0) 
Adenocarcinoma n=16 1.9± 1.2t (0.6 - 5.6) 
Squamous cell ca. n=7 1.1 ± 0.5 (0.6 - 2.0) 
"'pmol/mg protein/hour, mean ± SD; t p<O.05, :t:p<O.01 
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Discussion 
Several groups have shown that porphyrins accumulate in neoplastic tissue after the 
administration of ALA (Peng et al., 1997, review). Normally, heme synthesis is regulated 
by substrate availability and by feedback inhibition of the enzyme ALA synthase. The 
concentration of substrates and intermediates are usually far below the Michaelis con-
stants of the enzymes, in which case intermediates are metabolized to heme (Bottomly 
& Muller-Eberhard, 1988). When exogenous ALA is administered, normal cells will rap-
idly produce heme. An excess of exogenous ALA will initially overload the system and 
porphyrin intermediates will accumulate. The presence of the intermediates contributes 
to photosensitivity of normal cells, but these intermediates are rapidly metabolised into 
heme. In malignant and pre-malignant tissue of the oesophagus, we found increased 
PBG-D and Fe activities compared to normal squamous epithelium, and an imbalance 
between these activities. These results are in line with those found in our previous small-
er studies (Hinnen et al., 1997a, 1997b). Due to individual patient and tissue variations 
in the activities of PBG-D and Fe, also described by others (Dailey & Smith, 1984; el-
Sharabasy et al., 1992; Navone et al., 1990; Rubino & Rasetti, 1966; Schoenfeld et al., 
1987, 1988a, 1988b; Smith, 1987; Van Hillegersberg et al., 1992), the activity of these 
two heme enzymes can be better described relative to each other. This ratio, which we 
propose to call the PDT power index, reflects the enzymatic ability of cells to accumulate 
porphyrins after ALA administration and might predict the susceptibility of tissue to ALA-
PDT. The PDT power index was significantly increased in Barretts epithelium and ade-
nocarcinoma compared to normal squamous epithelium indicating that the Fe activity 
was relatively low compared to the PBG-D activity. Since this index can also be derived 
from biopsy specimens, e.g. oesophagus or Barrett, it could be applied prior to ALA-PDT 
to estimate tissue susceptibility. increased PBG-D activity relative to normal tissue has 
consistently been found in tumours (el-Sharabasy et al., 1992; Navone et al., 1990, 1991; 
Schoenfeld et al., 1988a) as well as in rapidly dividing cells, e.g. regenerating liver cells 
(Schoenfeld et al., 1987, 1988b), suggesting that this phenomenon might be common in 
situations of increased cell replication. in contrast with the consistent studies concerning 
the activity of PBG-D, there seems to be a difference in Fe activity among different 
tumour types (Dailey & Smith, 1984; el-Sharabasy et al., 1992; Rubino & Rasetti, 1966; 
Smith, 1987; Van Hillegersberg et al., 1992). Dailey and Smith (1984) found a decreased 
Fe activity in the Morris hepatoma model, however they also pointed out that some por-
phyrins can act as inhibitors of Fe. Smith (1987) found decreased Fe activities in human 
skin tumours but also in normal skin tissue compared to those in rat liver mitochondria. 
EI-Sharabasy et al. (1992) determined the Fe activity in whole blood samples of children 
and adults with acute lymphoblastic leukaemia (ALL), non-Hodgkin's lymphoma (NHL) 
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or Hodgkin's disease (HD) and found lowered activities in patients with ALL, slightly 
decreased activities and increased activities of FC in blood of patients with NHL and HD 
respectively compared to healthy control groups. Compared to liver, which is one of the 
main heme-synthesizing tissues, most tissues have low enzyme activities (Webber et al., 
1997). Our group found the FC activity to be decreased in a colon carcinoma liver metas-
tasis model and we suggested applying ALA-PDT to patients with these liver metastases 
(Van Hillegersberg et al., 1992). Regarding the effect of the storage temperature on FC 
activity, interpretation of data from other studies might be biased due to differences in 
tissue storage. In the gastrointestinal tract, accumulation of porphyrins after ALA admin-
istration, is more pronounced in the mucosa than in the underlying submucosa and mus-
cle layers making ALA suitable for treating most mucosal lesions (Bedwell et al., 1992; 
Loh et al., 1993; Webber et aI., 1997). In patients with familial adenomatous polyposis, 
no differences in PPIX concentrations were found between normal and adenomatous tis-
sue (Mlkvy et al., 1995). In the DMH rat colonic tumour model the same group showed 
differences in the levels of PPIX between normal mucosa and tumour with a ratio of 1:6 
(Bedwell et al., 1992). In another study they showed that higher doses of ALA (60 
mg/kg instead of 30 mg/kg) improved the tumour:normal mucosa PPIX sensitisation 
ratio in patients with colon carcinoma (Regula et al., 1995). Webber et al. (1997) 
showed selective accumulation of PPIX in adenocarcinomas of the gastrointestinal tract 
in 42 patients. Our biochemical study has characterized the enzymatic capacities of 
heme biosynthesis in normal, pre-malignant and malignant tissue of the human oesoph-
agus. These results provide evidence for the selectivity of PPIX accumulation between 
normal and neoplastic tissue of the oesophagus. Whether selective PPIX accumulation 
creates the possibility of achieving selective necrosis is still in question. Recently, Bown 
and Millson (1997) have stated that the selectivity of ALA-PDT induced necrosiS, in the 
gastrointestinal tract, is between mucosa and underlying submucosa and muscularis and 
not between normal mucosa and neoplastic mucosa. In conclusion our study supports 
the use of ALA for selective PDT in Barrett's oesophagus and early carcinoma. 
Information about the PDT power index could be useful in predicting the effect of ALA 
administration on porphyrin accumulation and therefore on the susceptibility of the dis-
order to ALA-PDT. 
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Operating lights and acrylate yel/ow filters 
Abstract 
Background: Photosensitized patients are exposed to bright lights when undergoing intra-
operative photodynamic therapy or fluorescence measurements. Acrylate yellow filters might 
reduce unwanted tissue damage. Method: To investigate the protective value of these filters, 
the spectral power distribution of the operating lights and light energy densities with and 
without an acrylate yellow filter were measured. Subsequently, the effects of light exposure 
on the survival of a human hepatocellular carcinoma cell line and the photodamage induced 
in pig tissues after the administration of 5-aminolevulinic acid were also studied. Results: The 
light energy density in the ultraviolet and blue light region of the light spectrum emitted by 
the operating light was reduced up to 50 percent by the acrylate yellow filter. The survival of 
photosensitized cells was longer and photodamage induced in pig tissues was less when 
exposed to filtered light. Conclusion: Photodamage induced by operating lights can be 
reduced by filtering out ultraviolet and blue light by means of acrylate yellow filters. 
Introduction 
Photodynamic therapy (PDT) has been proposed as an adjuvant to cancer surgery to 
reduce local recurrence. PDT during operation is complicated by the fact that photosen-
sitized patients are exposed to operating lights in addition to the light source used for 
PDT (Abulafi et al., 1997; Allardice et al., 1994; van Hillegersberg et al., 1995). The pro-
toporphyrin IX (PPIX) precursor, 5-aminolaevulinic acid (ALA) is currently under study as 
a potential photosensitizer for gastrointestinal cancer (Hinnen et al., 1998). PPIX is 
formed by both tumour and normal tissues, and normal organs are also vulnerable if 
exposed to light of a broad spectrum during the period of PPIX accumulation (Sown and 
Millson, 1997; Loh et al., 1993). 
This investigation aimed to determine whether the use of acrylate yellow filters, which 
filter out the shorter wavelengths of the spectrum of the operating lights (ultraviolet (UV) 
and blue region), might reduce tissue damage. Others have also used these filters as a 
safety measure when operating on photosensitized patients, but their protective value 
does not appear to have been studied (Fromm et al., 1996; Meerman et al., 1994; 
Webber et al., 1997). 
First, the survival of a human hepatoma cell line, HepG2, was studied after incubation 
with ALA and subsequent exposure to operating lights with and without an acrylate yel-
low filter (iwasa et al., 1989; Visser et al., 1991). Second, the effect of acrylate yellow 
filters on pigs being exposed to an operating light during a laparotomy following admin-
istration of ALA was determined. 
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Materials and methods 
LIGHT SOURCE AND ACRYLATE YELLOW FILTER 
An Angenieux operating light type AA 14 (Gambro Med',sche Apparaten, Breda, The 
Netherlands) with 2 halogen bulbs (150W) was used for the HepG2 cell line study. The 
spectral power distribution was determined by a MultiSpec 125 spectrometer attached 
to a InstaSpec IV CCD camera (Oriel Instruments Corporation, Stratford, CT, USA). A 
Bechtold C- 571 operating light (Colombus Medical BV, Zaltbommel, The Netherlands) 
with essentially the same spectral power distribution was used for the pig experiments. 
The acrylate yellow 303 filter (4 mm thickness) was obtained from Wientjes (Roden, The 
Netherlands) and cut to fit the operating lights. 
HEPG2 CELL LINE STUDY 
HepC2 cells 
Hep G2 cells were grown as described previously (Visser et al., 1991), harvested at the 
moment of exponential growth and seeded in six-well plates at about 0.5 x10' cells per 
well. 
Porphyrin analysis 
Porphyrins were measured by a modification of the method by Chisolm and Brown 
(Chisolm and Brown, 1975) as described previously (van den Boogert et al., 1998), and 
expressed as picomoles per 10' cells. 
Irradiation 
Cells were incubated with or without 0.3 mmol/L ALA for 2 h under conditions 
described by Vonarx et al (Vonarx-Coinsman et al., 1995). Following incubation, cells 
were cultured for 3 h without ALA. Subsequently, they were exposed for 0, 5, 10, 15 
or 20 min to filtered or unfiltered focused light, at 40 cm. Thereafter, cells were cul-
tured until cell viability was determined by the trypan blue exclusion test at 24 h after 
irradiation. 
PIG EXPERIMENTS 
ALA administration 
Experiments were performed on 2 male pigs weighing 21.5 and 22 kg. After fasting for 
24 hand 12 h without water, the pigs were sedated with 5 ml ketamine intramuscular-
ly (100 mg/ml; Apharmo Holland, Arnhem, The Netherlands). ALA 75 mg/kg (Fluka, 
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Buchs, Switzerland) in 150 ml phosphate-buffered saline was administered by gavage. 
Blood samples were taken. 
Laparotomy and irradiation 
Pigs were anaesthetised with 70 percent nitrous oxide and 30 percent oxygen, 2 percent 
enflurane (Abbott, Amstelveen, The Netherlands), 6 ml fentanyl citrate intravenously 
(0.05 mg/ml, Janssen-Cilag, Tilburg, The Netherlands) and 2 ml curare intravenously (2 
mg/ml; Organon Teknika, Boxtel, The Netherlands). Some 5 h after ALA, liver, small 
intestine and stomach surfaces were exposed to the focused operating light at 80 cm for 
30 min. Other organs were covered. One pig was exposed to filtered light, the other to 
unfiltered light. Light power densities (mW/cm2) were measured using sterile photode-
tectors (coherent model 210 and the UDT model 81; United Detector Technology, Palo 
Alto, California, USA). Exposed areas were marked. Dark sides of the organs were used 
to assess dark toxicity. 
Post mortem examinations 
Some 48 h after laparotomy, pigs were sedated with 5 ml ketamine (100 mg/ml) and 
the organs were inspected by the same surgeon. The pigs were then killed and tissue sam-
ples were taken. 
Histological examinations 
Tissue samples were fixed with formalin, sectioned, stained with haematoxylin and eosin, 
and examined. 
LABORATORY MEASUREMENTS 
ALA and porphobilinogen (PBG) concentrations in plasma were determined using a flu-
orometric enzyme assay according to a procedure described by de Rooij et al. (de Rooij 
et al., 1987). Levels of alanine aminotransferase (ALAT) and aspartate aminotransferase 
(ASAT) in serum were determined (Granutest 25; Merck, Darmstadt, Germany). 
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Results 
SPECTRAL POWER DISTRIBUTION AND ACRYLATE YELLOW FILTER CHARACTERISTICS 
The maximum light power density of the operating light was 30 mW/cm2. The spectral 
power distribution of the operating lights with and without the acrylate yellow filter and 
the excitation spectrum of PPIX are shown in FIGURE 1. The filter eliminates nearly all UV 
and blue light below a wavelength of about 520 nm. 
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FIGURE 1 Spectral power distribution of an operating light with and without acrylate yellow filter, 
and the relative excitation spectrum of protoporphyrin IX (PPIX) 
HEPG2 CELL LINE STUDY 
HepG2 cells accumulated PPIX from exogenous ALA (results not shown). Exposure of 
cells to filtered light (protected cells) for 5 min resulted in a surviving fraction of 89 per-
cent 24 h later (FIGURE 2). Only 39 percent of the unprotected cells survived. This initial 
sixfold reduction in cell death decreased after longer exposure times. After 10 min expo-
sure, 35 percent of protected cells survived, compared to 18 percent of unprotected cells, 
and after exposure for 20 min the surviving fractions were 13 and 5 percent for protected 
and unprotected groups respectively. At all time points twice as many protected cells sur-
vived compared to unprotected cells. Non-irradiated ALA incubated as well as irradiated 
non-ALA-incubated cells multiplied throughout the experiment. The temperature of the 
medium remained constant in all groups. 
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FIGURE 2 Survival of photosensitized HepG2 cells, 24 h after 0, 5, 10, 15 and 20 min of expo-
sure to an operating light with (. ) and without (.1) an acrylate yellow filter 
PIG EXPERIMENTS 
ALA plasma concentrations, determined at various intervals, peaked at or before 4 h 
after ALA administration. At 24 h, ALA was not detectable in plasma. 
Light power densities in peripheral fields and in fields directly in focus were measured 
during the laparotomy, and varied from 0.1 to 21 mW/cm2 without the filter and from 
0.1 to 10 mW/cm2 with the filter. The total light energy densities reaching the liver, small 
intestine and stomach surfaces consisted of direct (focused) illumination for 30 min and 
indirect illumination (preparation time and peripheral light during exposure of other organ) 
for 75 min. Some 66-70 J/cm2 reached the organs without the filter and 34-36 J/cm2 
reached the organs with a filter. Therefore, a 50 percent reduction of total light energy 
density, mainly of UV and blue light (wavelength less than 520 nm; FIGURE 1), was 
caused by the filter. 
During exposure to unfiltered light, macroscopic changes included redness of the gastric 
serosa, a white contracting serosa of the small intestine, a colour change of the liver from 
brown to yellow, and a change to a wrinkled aspect of the liver surface. These changes 
were less pronounced after exposure to filtered light. 
At post-mortem examination, macroscopic changes after illumination without the filter 
were more pronounced. Haemorrhagic spots existed and the tissue was swollen com-
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pared with the dark control side of the same organ or tissue illuminated using the filter. 
Histologically, no changes were found in the dark control tissues of both pigs. There were 
clear differences in liver histology between areas illuminated with or without the filter 
(FIGURES 3 and 4). Liver necrosis was twice as deep when the filter was not used (1.0 
versus 0.5 mm). Necrosis was not seen in the stomach and small intestine, but oedema, 
leucocyte infiltration and disintegration of muscle cells were observed. Transient (for 48 
h) increases in ASAT concentrations were more pronounced in the pig operated on with-
out the filter. There was no skin damage or abnormal behaviour. 
FIGURE 3 Necrotic zone (1 mm) at the illuminated site of the liver surface without the filter. 
Arrows indicate towards the liver surface and demarcate the necrotic zone (original magnit;ca-
tion x 20) 
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FIGURE 4 Necrotic zone (0.5 mm) at the illuminated site of the liver surface with the filter. Arrows 
indicate towards the liver surface and demarcate the necrotic zone (original magnification x 20) 
Discussion 
PPIX is highly photosensitizing, as shown in the disease erythropoietic protoporphyria. 
Photochemical reactions are induced by UV and blue light (Todd, 1994). It seems rea-
sonable to protect patients undergoing surgery who have been photosensitized after ALA 
administration, by using filters that block UV and blue light. Acrylate yellow filters, which 
cut off wavelengths shorter than 520 nm, reduce the light energy density by 50 percent, 
mainly in the UV and blue light range (FIGURE 1). These filters were found to protect pho-
tosensitized HepG2 cells when exposed to operating lights for less than 5 min. With an 
exposure time exceeding 5 min, the filter failed to prevent cell death. However even after 
longer exposure, the survival rate of cells protected by the filter during irradiation was 
still twice as high as that of cells irradiated without a filter. Acrylate yellow filters also 
had a protective effect in pigs after ALA pretreatment. Both macroscopic and microscopic 
damage was less pronounced when the light was filtered. Energy densities in these 
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experiments were higher than the known energy densities provided to human tissues dur-
ing operation as measured by Allardice et al. (Allardice et al., 1989). These authors stud-
ied the safety of intraoperative PDT with haematoporphyrin derivative; however they 
defocused the operating lights at 1.30 m from the investigated area, creating minimum 
illuminance. Allardice and co-workers concluded that operating lights can reach unac-
ceptably high energy levels and that an additive dose given by intraoperative PDT might 
cause unwanted side-effects. They mentioned the possible use of yellow filters but con-
cluded that yellow light may be unacceptable to surgeons. The present study demon-
strates that acrylate yellow filters have a protective effect. However, after longer expo-
sure to filtered light, tissue damage is likely to occur and surgeons should probably still 
cover organs that are not in the immediate operating field to prevent unnecessary light 
exposure and damage. Some anatomical structures (e.g. ureters and hypogastric nerves) 
might have their colour appearance changed and surgeons should be aware that a colour 
change may hinder their recognition of structures. Meerman et al. (Meerman et al., 1994) 
used acrylate yellow filters during liver transplantations in patients suffering from ery-
thropoietic protoporphyria. The abnormal colour perception did not hamper the surgeons 
and other personnel. 
In the present authors' hospital, these filters were used in ten photosensitized patients 
during resection and reconstruction of the oesophagus. There was no deterioration in the 
visibility of structures and the use of these filters was fully acceptable to the surgeons. 
Surrounding lights in the operating theatre do not add much to the light energy density 
reaching the exposed organs (results not shown), so these lights can be kept on for the 
convenience of the nursing and anaesthetic personnel. 
In conclusion, the use of acrylate yellow filters is recommended when photosensitized 
patients are operated on, and also when porphyrin concentrations are to be measured in 
tissue obtained at operation, to minimize photoactivation. 
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Porphyrin biosynthesis in human oesophagus after ALA ingestion 
Summary 
5-Aminolaevulinic acid (ALA) induced porphyrin biosynthesis, which is used for ALA 
based photodynamic therapy (ALA-PDT), was studied in tissues of 10 patients with 
Barrett's oesophagus (BE) and adenocarcinoma of the oesophagus (AC) undergoing 
oesophagectomy at a mean time interval of 6.7 hours after the ingestion of ALA (60 
mg/kg). In BE, AC, squamous epithelium (SQ) and gastric cardia, the activities of the 
haem biosynthetic enzymes, porphobilinogen deaminase (PBG-D) and ferrochelatase 
(FC) and the PDT power index - the ratio between PBG-D and FC in BE and AC in com-
parison with SQ - were determined before ALA ingestion. Following ALA administration, 
ALA, porphobilinogen, uroporphyrin I and PPIX were determined in tissues and plasma. 
The PDT power index did not predict the level of intracellular accumulation of PPIX found 
at 6.7 hrs. In BE, there was no selectivity of PPIX accumulation compared to SQ, where-
as in half of patients with AC selectivity was found. Higher haem biosynthetic enzyme 
activities (i.e. PBG-D) and lower PPIX precursor concentrations were found in BE and AC 
compared to SQ. It is therefore possible that PPIX levels will peak at earlier time inter-
vals in BE and AC compared to SQ. 
Introduction 
Barrett's oesophagus (BE) is a pre-malignant condition in which progression from meta-
plasia to low-grade dysplasia and high-grade dysplasia could lead to invasive adenocarci-
noma of the oesophagus (AC) (Drewitz et al., 1997; Hameeteman et al., 1989; van der 
Burgh et al., 1996). High-grade dysplasia is often regarded as an indication for 
oesophagectomy (Cameron and Carpenter, 1997; Clark et al., 1996; Edwards et al., 
1996). A possible alternative, which is less mutilating and also applicable in patients with 
a high surgical risk is 5-aminolaevulinic acid-induced photodynamic therapy (ALA-PDT). 
Two relevant clinical studies have been performed, in which patients with high-grade dys-
plasia or early cancer in BE received an oral dose of ALA (60 mg/kg), followed by pho-
toactivation 4-6 hours later (Barr et al., 1996; Gossner et al., 1998). Both high-grade dys-
plasia and early cancer were eradicated allowing regeneration of squamous epithelium 
without scarring or stricture formation. However, the presence of islands of columnar 
cells remaining beneath regenerating squamous epithelium created the concern that 
superficial healing could mask underlying dysplasia. These results suggest that ALA-PDT 
needs to be improved. 
Haem biosynthesis, an essential process in every cell, is the basis of ALA-PDT (FIGURE 1). 
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FIGURE 1 Haem biosynthetic pathway 
ALA is the first intermediate, and two molecules of ALA are converted to 
porphobilinogen (PBG) which is metabolised to porphyrinogen intermediates by por-
phobilinogen deaminase (PBG-D). The last step of haem biosynthesis is the insertion 
of iron into PPIX by ferrochelatase (FC). Normally, haem synthesis is regulated by 
feedback inhibition of the enzyme ALA synthase. Exogenous ALA bypasses this feed-
back inhibition and the activities of PBG-D and FC and the intracellular iron pool 
become rate-limiting factors. As a result porphyrins, predominantly PPIX, will accu-
mulate (Bishop and Desnick, 1982; Kennedy and Pottier, 1992). Previously, we 
observed an imbalance between the activities of PBG-D and FC in BE and AC (Hinnen 
et al., 1998). The ratio between PBG-D and FC activities, normalised for squamous 
epithelium, was found to be significantly higher in BE and AC. In that study, we sug-
gested that this ratio, which we have called the PDT power index, might be a useful 
parameter for predicting the accumulation of PPIX in tissues after the administration 
of ALA. 
In this study, we examined the relation between the PDT power index and the intra-
cellular concentration of PPIX in tissues of patients with BE and AC at approximately 
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6 hours after ALA ingestion (60 mg/kg) as this is the clinically most frequently used 
time interval. We determined the intracellular concentrations of ALA and other haem 
intermediates by biochemical extraction methods rather than fluorescence microscopy 
as used by others (Barr et al., 1996; Regula et al., 1995). In addition, plasma phar-
macokinetics of ALA and porphyrins were studied and side effects were monitored. 
Materials and methods 
PATIENTS 
In total 10 patients (2 women and 8 men; age 44 - 81 years; mean age 65 years) gave 
their written informed consent to participate in this study, which was approved by the 
Medical Ethical Committee of the University Hospital Rotterdam. Nine patients with his-
tologically proven AC in BE and one patient with high-grade dysplasia in BE underwent 
an oesophageal resection with a gastric tube interposition. One patient was excluded 
from analysis because the tissue samples taken from BE were contaminated with AC as 
samples were taken at the border between BE and AC. 
STUDY DESIGN 
Biopsy samples (pre-5-aminolaevulinic acid administration) 
Apart from one patient, all patients underwent an endoscopy with biopsies taken from 
BE, AC as well as from normal gastric cardia mucosa (GC) and normal squamous epithe-
lium (SO). Biopsies were embedded in formalin, sectioned, and stained with hematoxylin 
and eosin. The grade of tumour differentiation and the grade of dysplasia in Barrett's 
mucosa were described according to Haggitt (Haggitt, 1994). In addition, adjacent biop-
sies were kept at -lO°C until the activities of PBG-D and FC and porphyrin concentrations 
were determined (Hinnen et al., 1998). 
5-Aminolaevufinic acid administration 
Six hours before the oesophageal resection, ALA (Fluka, Buchs, Switzerland, 60 mg/kg) 
was dissolved in orange juice (10 ml, at room temperature) and given to the patient. 
Following this, all patients drank an additional 30 ml of water. 
Photodegradation of porphyrins and photosensitization tissue damage during exposure 
to the operating lights was prevented by covering the tissues not in the immediate oper-
ating field with gauzes and shielding the operating lights with acrylate yellow filters 
(Wientjes B. V, Roden, The Netherlands), which eliminate nearly all UV and blue light 
below a wavelength of about 520 nm (Hinnen et al., 2000a). For 48 hours after the 
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administration of ALA, patients were kept in subdued light. Side effects were monitored 
by questionaires and physical examination. 
Blood samples 
Venous blood samples were collected prior to and at 1, 3, 6, 9, 12, 24 and 48 hours 
after the administration of ALA. Whole blood was collected in tubes wrapped in alu-
minum foil to prevent photoconversion and photodamage, and kept on ice. The blood 
samples were centrifuged at 1300 x g for 10 min, then the plasma was removed, pro-
tected from light and stored at -lO°C until the determinations of ALA, porphobilinogen 
(PBG), uroporphyrin (URO) and PPIX. In addition, samples were collected for routine bio-
chemistry (urea, creatinine, sodium, potassium, albumine, alkaline phosphatase, bilirubin, 
aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT». 
Tissue samples (post-5-aminofaevulinic acid administration) 
Immediately after the oesophageal resection, tissue samples were taken from BE, AC, SQ 
and GC for histological examination. Adjacent tissue samples were kept at -lO°C until 
the determinations of ALA, PBG, URO and PPIX. It was not always possible to take tis-
sue samples at exactly 6 hours after the admin',stration of ALA as in some patients the 
start of the operation was delayed by the prolonged anaesthetic preparations and in oth-
ers the anaesthetic procedure was complicated by hypotension (see side effects). 
However 6 of 9 patients were sampled at about 6 ± 0.5 hours. 
LABORATORY ASSAYS 
Chemicals 
PPIX disodium salt, Zinc-PPIX and PBG were obtained from Porphyrin Products (Logan, 
UT, USA). Coproporphyrin, URO and Triton X-100 were obtained from Sigma Chemical 
Co. (St. Louis, MO, USA). Tris-HCL was obtained from Boehringer Mannheim 
(Mannheim, Germany) and all other chemicals were obtained from Merck (Darmstadt, 
Germany). 
Porphobilinogen deaminase and ferrocheJatase assays 
Tissue samples, kept on ice, were homogenised in water (1/5, wt/wt) using a Potter 
Elvehjem homogenizer (Kontess Glass Co., Vineland, NJ, USA). PBG-D and FC activities 
as well as the PDT power index - the ratio between PBG-D and FC in BE and AC in com-
parison with SQ - were determined as described previously (Hinnen et al., 1998). Data 
were expressed as pmolj mg protein/ hour. Protein was determined according to the 
method of Lowry et al. (Lowry et al., 1951). 
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Determinations of 5-aminolaevulinic acid, porphobilinogen, uroporphyrin and protoporphyrin 
IX in plasma and tissue 
The analysis of ALA and PBG was performed as described previously (van den Boogert 
ef al., 1998). URO was extracted from 25 ~I tissue homogenate or plasma (twofold dilut-
ed in NaCI (150 mmol/L)) by addition of 200 ~I of URO extraction buffer (UEB; Tris-HCI 
50 mmol/L, pH 8.0; trichloroacetic acid, 15 mol/L in aqua dest., (3/5, v/v)). After 5 
min exposure to UV light (350 nm), to convert porphyrinogens into porphyrins, the sam-
ples were centrifuged for 7 min at 3000 x g. 
The fluorescence of the supernatant was measured at an excitation wavelength of 410 
nm and an emission wavelength of 656 nm using a LS 50B spectrofluorometer with a 
red sensitive photomultiplier (Perkin Elmer, Nieuwerkerk aid Ussel, The Netherlands). 
Values were calculated according to a standard curve of URO I in UEB. Recovery of por-
phyrins during the extraction was determined by adding standard URO to the samples 
and in this study recoveries were found in the range of 85-100%. 
PPIX was extracted from tissue by adding 50 ~I PPIX extraction buffer (PEB; Tris-HCI 50 
mmol/L, pH 8.0; 425 ~I dimethylsulfoxide/methanol, (DMSO/MeOH, 30/70, v/v)) to 
25 ~I tissue homogenate. The diluted homogenate was mixed vigorously using a vortex 
and left for about 30 min at room temperature. Samples were then centrifuged for 10 
min at 3000 x g. 100 ~I of supernatant was injected on a HPLC as described previously 
(Van Hillegersberg ef al., 1992), however using an excitation wavelength of 415 nm and 
an emission wavelength of 630 nm. For the extraction of PPIX from plasma, 950 ~I of 
PEB was added to 50 ~I plasma. Values were calculated according to standard curves of 
Zinc-PPIX and PPIX in DMSO/MeOH (30/70, v/v). Recovery of porphyrins during the 
extraction was determined by adding standard Zinc-PPIX and PPIX to the samples and in 
this study recoveries were found in the range of 90-100%. Plasma levels were expressed 
in nmol/L and tissue levels in pmol/ mg protein. 
PROTOPORPHYRIN IX AND ITS PRECURSORS 
At 6 hours after ALA administration, tissues not only contained PPIX but also other haem 
synthesis intermediates, which are the precursors of PPIX and therefore considered as 
potential PPIX. Since the concentration of URO was very low in tissue and plasma sam-
ples compared to PPIX, the URO data were omitted from further analysis. PBG is formed 
from two molecules of ALA and 4 molecules of PBG form a PPIX molecule. To calculate 
the potential PPIX molecules, present at 6 hours after ALA administration, the concen-
trations of ALA and PBG were divided by 8 and 4 respectively and we called this "PPIX 
equivalents" . 
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STATISTICAL ANALYSIS 
Data are expressed as means ± sem and were tested for statistical significance using 
Student's t-test for paired values. Enzyme activities and concentrations of haem interme-
diates in BE, AC and GC were compared to SO. Pearson correlation coefficients were cal-
culated to study possible correlations. P-values <0.05 were considered significant. 
Results 
PORPHOBILINOGEN DEAMINASE AND FERROCHELATASE ACTIVITIES AND PDT 
POWER INDEX 
Before oral ALA administration, PBG-D and FC activities were determined in endoscopi-
cally derived biopsy samples taken the oesophagus (BE, AC and SO) and the proximal 
stomach (GC). A twofold increase in PBG-D activity (pmolj mg protein/ hr) was found 
in BE (39.18 ± 5.67, P ~ 0.013) and in AC (38.76 ± 3.98, P ~ 0.001) compared with SO 
(19.72 ± 2.85), whereas the activity in GC (21.46 ± 1.27) was not different from the 
activity in SO (TABLE 1). The activities of Fe (pmolj mg protein/ hr) were not significantly 
different in BE (696 ± 89, P ~ 0.06) and AC (532 ± 68, P ~ 0.36) compared to SO (444 
± 49), whereas the FC activity in GC (688 ± 38, P ~ 0.02) was significantly increased. 
In BE, the PDT power index (1.4 ± 0.2, P ~ 0.18) was not significantly different from SO 
(1.0). in AC, this index was significantly increased (1.9 ± 0.3, P ~ 0.01) whereas in GC 
the index was significantly decreased (0.7 ± 0.1, P ~ 0.01) compared to SO. 
PROTOPORPHYRIN IXAND PROTOPORPHYRIN EQUIVALENTS CONCENTRATION IN 
TISSUE 
Tissue samples of 9 patients were collected at a mean time interval of 6.7 ± 0.5 hours 
(range 5.25 - 10) after the administration of ALA. All tissue types contained the same 
concentrations of ALA-PPIX equivalents (TABLE 1). In BE, AC and GC, the intracellular 
concentration of PBG-PPIX eqUivalents were significantly lower than in SO. 
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TABLE 1 
Haem biosynthetic enzyme activities before ALA ingestion and the concentrations of PPIX and 
"PPIX equivalents" (pmol/mg protein) at a mean time interval of 6.7 hrs after ALA ingestion 
(60 mg/kg) in gastro~esophageal tissues of 9 patients. 
"PPIX "PPIX 
tissue equivalents" equivalents" PBG-D Fe PDT power 
type ALA/8 PGB I 4 PPIX activity activity index 
SQ 134 ± 38 312 ± 59 92 ± 15 20 ± 3 444 ± 49 1.0 
BE 132 ± 39 201*±38 77 ± 17 39* ± 6 696 ± 89 1.4±0.2 
AC 101 ± 38 126* ± 30 112 ± 45 39* ± 4 532 ± 68 1.9*±0.3 
GC 61 ± 19 129* ± 29 57* ± 10 21 ± 1 688*± 38 0.7* ± 0.1 
SQ, squamous epithelium; BE, Barrett's oesophagus; AC, adenocarcinoma; GC, gastric cardia; PSG-D, porpho-
bilinogen deaminase; FC, ferrochelatase, enzyme activities in pmol/ mg protein/ hour; PDT power index, ratio 
between PBG-D and FC normalised for So. 
... p< 0.05 compared to SQ 
The individual variability in the concentration of PPIX is demonstrated in TABLE 2 togeth-
er with the patients and tissues characteristics. PPIX was the main metabolite of ALA 
found in tissue. Undetectable levels of porphyrins were found in tissue samples of any of 
the 9 patients when taken before the oral administration of ALA (results not shown). 
The concentration of PPIX in BE (77 ± 17) was not significantly different from SQ (92 ± 
15), whereas the concentration in GC was significantly lower (57 ± 10, P ~ 0.01) (TABLE 
1). Only one patient (TABLE 1, patient 5) showed a selective accumulation of PPIX in BE 
compared with SQ. Levels of PPIX did not depend on the grade of dysplasia found in BE. 
The concentration of PPIX in AC (112 ± 45) was not significantly different from SQ (92 
± 15) (TABLE 1). Selective accumulation of PPIX was seen in four cases of AC. Of the 
remaining four cases of AC, in one patient tissue was obtained at 10 hours after the 
administration of ALA and in the other three cases the AC was histologically found to be 
poorly differentiated. 
The PDT power index did not correlate with the levels of PPIX found. 
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TABLE 2 
Patient and tissue characteristics of 9 patients after the oral administration of 60 mg/kg ALA. 
Age Tumour Grade of Sampling PPIX PPIX PPIX PPIX 
(yrs) Sex diff grade dysplasia time (hrs) SQ BE AC GC 
1 51 M moderately LGD 10 86 46 31 67 
2 45 M moderately ND 5.25 55 55 82 60 
3 79 F HGD 6.16 172 173 125 
4 73 M well LGD 6 51 40 78 36 
5 69 M poorly ND 7.83 85 107 142 54 
6 72 M poorly ND 6 80 84 60 44 
7 77 F poorly ND 6.67 68 24 50 36 
8 63 M poorly LGD 7.83 60 34 37 26 
9 45 M moderately LGD 6 168 127 414 64 
NO, no dysplasia; LCD, low grade dysplasia; HCD, high grade dysplasia. Sampling time (hrs), sampling time in 
hours after ALA. PPfX concentrations (pmol/mg protein) in SQ, squamous epithelium; BE, Barrett's oesopha-
gus; AC, adenocarcinoma; GC, gastric cardia. Data in bold, selective accumulation of PPIX compared to other 
tissue samples of the same patient. 
PHARMACOKINETICS OF 5-AMINOLAEVULINIC ACID, PORPHOBILINOGEN AND 
PROTOPORPHYRIN IX IN PlASMA 
Plasma ALA, PBG, and PPIX kinetics are shown in FIGURE 2. After the initial absorption and 
distribution phase the decrease in ALA, PSG and PPIX followed first-order kinetics with half 
lives of 1.8, 5.9 and 6.7 hours respectively. The range in the half lives of ALA, PBG and 
PPIX between different patients was considerable: 1.1-2.5 hours for ALA, 4.1-11.6 hours 
for PBG and 2.5-12.8 hours for PPIX. In all patients. peak concentrations of ALA were 
detected at 1 hour and concentrations declined to baseline levels at 24 hours after admin-
istration. There was a considerable variability between patients in the time to achieve the 
peak plasma concentrations of PBG and PPIX (range: 6-12.3 hours). Plasma concentrations 
of PBG and PPIX declined to baseline levels at 48 hours after ALA ingestion. 
SIDE EFFECTS 
Side effects were vomiting, skin photosensitivity. hypotension and transient increases of 
ASAT and ALAT. Eight patients suffered from at least one of these side effects. Three 
patients vomited inCidentally between 2.5 - 4.5 hours after the administration of ALA. 
ASAT and ALAT were elevated 2 to 3-fold above normal levels in 6 patients and peaked 
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at day 2 after ALA administration. Mild skin photosensitivity, characterised by itching and 
mild erythema was present in 7 patients. One patient had severe edema of his facial skin, 
lips and tongue. The symptoms improved spontaneously within 24 hours. Hypotension 
was found in 5 patients, in 4 patients intra-operatively, within 6 hours after the admin-
istration of ALA. The mean systolic blood pressure of these patients dropped from 125 
mm Hg to 70 mm Hg and the mean diastolic blood pressure from 70 mm Hg to 40 mm Hg. 
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FIGURE 2 Pharmacokinetics of ALA, PSG and PPIX in plasma of 10 patients after ingestion of ALA 
(60 mg/kg). The plasma concentrations are expressed as log-values (y-axis, means ± sem). 
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Discussion 
In patients with AC in BE we previously found increased activities of PBG-D and FC in 
endoscopic biopsies of BE and AC compared with SQ (Hinnen et al., 1998). Based on 
this observation we proposed a PDT power index, the ratio between PBG-D and FC activ-
ity in BE and AC in comparison with SQ. We suggested that this index could be of value 
in predicting porphyrin concentrations in these tissues after ALA administration. 
Under the conditions chosen in the present study, however, the PDT power index did not 
predict the level of intracellular PPIX accumulation found at a mean time interval of 6.7 
hours after ALA administration in BE, AC, SQ and GC in these patients. It is possible that 
a relationship still exists between the PDT power index and PPIX accumulation at anoth-
er time interval as we found higher enzyme activities and lower PPIX precursor concen-
trations in AC and BE compared to SQ (TABLE 1). It is therefore possible that PPIX levels 
could have peaked at earlier time intervals in BE and AC compared to SQ. 
As found by others, who determined PPIX by fluorescence microscopy, an indirect, semi-
quantitative method (Barr et al., 1996; Regula et al., 1995), there seemed to be little 
selectivity of PPIX accumulation in BE. In contrast, we found selective accumulation of 
PPIX in 4 of 8 cases of AC. The other four AC samples contained only low levels of PPIX, 
as compared to SQ. In three of these cases the histology showed a poorly differentiated 
tumour. It has been reported that the grade of differentiation can have a negative or pos-
itive effect on the ability of cells to accumulate porphyrins, depending on the type of tis-
sue (Li et al., 1999). In the fourth patient without selectivity between AC and SQ, tissue 
was collected at a rather late time (10 hrs) after the administration of ALA, at which time 
PPIX could already have been converted into haem. 
Not only is the absolute intracellular PPIX concentration an important factor for the 
effect of PDT but also the intracellular localisation of PPIX at the time of application of 
PDT, the duration of illumination and the flux of PPIX in cells (Hinnen et al., 2000b; 
linuma et al., 1994). If oxygen levels are high enough, more PPIX molecules per time unit 
result in a greater oxygen radical yield, and therefore will have a more pronounced effect 
(Henderson and Dougherty, 1992). 
The rapid kinetics of ALA and PPIX found in plasma (FIGURE 2) explain why ALA is an 
attractive pro-drug for PDT. PPIX in plasma is derived from liver and other cells and the 
decline in plasma levels reflect a decline in tissue levels (van den Boogert et al., 1998). 
Because of this rapid decline in PPIX levels, skin photosensitivity is only short-lasting (Barr 
et al., 1996; Gossner et al., 1998). 
A severe side effect observed in this study was hypotension. Herman et al. recently stud-
ied the hemodynamic effects of ALA. A relevant observation in that study was a signifi-
cant decrease in the systolic and diastolic blood pressure in all 6 patients (Herman et al., 
60 
Porphyrin biosynthesis in human oesophagus after ALA. ingestion 
1998). Goldberg et al. found in animal studies evidence for an ALA-triggered histamine 
release, which could result in vasodilatation and in that way hypotension (Goldberg and 
McGiliion, 1973). Based on these findings we treated four of our patients with anti-hist-
aminic agents and corticosteroids prior to ALA administration, but this failed to prevent 
hypotension in all of them. Haemodynamic stability was restored by infusion of isotonic 
fluids and plasma. It is presently not clear whether ALA, PPIX or a metabolite is respon-
sible for this side-effect. 
In conclusion, this study describes the photodynamic potential of the haem biosynthetic 
pathway in tissues of patients with BE and AC. At a mean time interval of 6.7 hours after 
ALA administration, PPIX accumulation could not be predicted from the PDT power 
index. Selectivity of PPIX accumulation was found in half of the cases of AC but not in 
BE. The optimum time interval is still not established but is possibly found at an earlier 
time interval after ALA administration. Side effects after ingestion of 60 mg/kg ALA can 
be serious and a hypotensive response can occur. Optimising the results of ALA-PDT in 
the treatment of BE and AC requires further effort in studies concerning the kinetics of 
ALA and its products in target tissues. 
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Pharmacokinetics of ALA and PPIX in human Barrett's oesophagus 
Abstract 
Background & Aims: 5-Aminolaevulinic acid- induced photodynamic therapy (ALA-PDT) 
is being used as an experimental treatment of Barrett's oesophagus (BE), a pre-malignant 
lesion in the distal oesophagus. Knowledge of the pharmacokinetics of ALA and the pho-
tosensitizer protoporphyin IX (PPIX) in tissues and plasma of patients with BE could help 
to determine the optimal time interval between the administration of ALA and illumina-
tion. 
Methods: Twenty six patients with BE were randomized to varying time intervals 
between ingesting 60 mg/kg ALA and undergoing an endoscopy with biopsies of BE and 
normal oesophageal and gastric mucosa. At 1, 2, 7, 8 and 24 h, two patients at each 
time and at 3, 4, 5 and 6 h, 4 patients at each time after ALA ingestion were included. 
ALA, porphyrin intermediates and PPIX were determined in all biopsy and plasma sam-
ples. 
Results: The maximum concentration of PPIX was found earlier in BE (4.6 ± 0.5 h) than 
in SQ (6.6 ± 2.2 h) (p<0.05). PPIX concentrations were higher in SQ than in BE espe-
cially at longer time intervals. In addition, tissue ALA concentrations were found to be 
20-fold higher than the plasma concentrations at 1 hour after ALA ingestion, suggesting 
uptake from the oesophageal lumen. Skin photosensitivity is short-lasting but often debil-
itating. 
Conclusions: Our results provide a rationale for the use of ALA-PDT for the treatment of 
BE at 4-5 h after ALA ingestion and for local application of ALA in the oesophagus. 
Introduction 
Barrett's (columnar-lined) oesophagus (BE) is a pre-malignant condition which is induced 
by chronic gastro-oesophageal reflux (Winters et al., 1987). Patients with BE have a 30-
125 fold increased risk for oesophageal cancer, compared with the general population 
(Drewitz et al., 1997; Hameeteman et al., 1989; van der Burgh et al., 1996). 
Adenocarcinoma of the oesophagus results from a multistep process of progression from 
metaplasia to low-grade dysplasia, high-grade dysplasia and ultimately invasive cancer 
(Hameeteman et al., 1989; Hamilton and Smith, 1987). A way to interfere in this 
sequence of increasing risk of developing malignancy is to apply 5-aminolaevulinic acid-
induced photodynamic therapy (ALA-PDT), an experimental non-invasive therapy, to 
remove Barrett's mucosa. 
To date, two clinical studies have been performed, in which patients with high-grade dys-
plasia or early cancer in BE received an oral dose of ALA (60 mg/kg), followed 4-6 h later 
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by photoactivation. Both high-grade dysplasia and early cancer were eradicated and this 
was followed by regeneration of squamous epithelium under proton pump inhibiting ther-
apy (Barr et al., 1996; Gossner et al., 1998). As ALA induces higher concentrations of 
PPIX in mucosa than submucosa or muscularis mucosa, superficial damage is achieved, 
leaving the muscle layer intact (Loh et al., 1993). However, the presence of islands of 
columnar cells beneath regenerating squamous epithelium created the concern that 
superficial healing could mask underlying dysplasia (Barr et al., 1996; Biddlestone et al., 
1998). The basis of ALA-PDT is the heme biosynthetic pathway (FIGURE 1). Two mole-
cules of ALA are converted to porphobilinogen (PBG), which is metabolized to por-
phyrinogen intermediates by porphobilinogen deaminase (PBG-D). The last step of the 
heme synthesis is the insertion of iron into PPIX, catalysed by ferrochelatase (FC). 
Normally, heme synthesis is regulated by feedback inhibition of the enzyme ALA syn-
thase. Exogenous ALA bypasses this feedback inhibition and the activities of PBG-D and 
FC and the intracellular iron pool become rate-limiting factors. As a result porphyrins, pre-
dominantly PPIX, will accumulate (Bishop and Desnick, 1982; Hinnen et al., 2000a; 
Kennedy and Pottier, 1992). 
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FIGURE 1 The haem biosynthetic pathway 
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In a previous study, we observed an increased ratio between PBG-D and FC activities in 
BE and adenocarcinoma of the human oesophagus (AC) compared to normal squamous 
epithelium (SO) (Hinnen et al., 1998). In a subsequent study we found that PPIX con-
centrations in BE and AC at a mean time of 6.7 h after ALA ingestion (60 mg/kg) were 
not higher than those in SO. The results also suggested that the rate of porphyrin biosyn-
thesis was higher in BE compared to SO (Hinnen et al., 2000a). This lead us to hypoth-
esize that maximum PPIX concentrations could be reached at an earlier time than 6-7 h 
after the oral administration of ALA in BE than in SO. Little detailed knowledge of the 
pharmacokinetics of ALA and PPIX in BE, SO and normal gastric mucosa (GC) as well as 
in plasma of patients with BE is available. Such information could help to optimize treat-
ment parameters such as the interval between the administration of ALA and illumina-
tion. For that reason, we performed a time sequence study and determined ALA, PBG, 
uroporphyrin and PPIX in tissue and plasma of patients with BE at varying time intervals 
after the oral administration of ALA. 
Materials and methods 
PATIENTS 
Twenty six patients (9 women and 17 men; age 34 - 74 years; mean age 55 years) with 
histologically proven BE gave their written informed consent to participate in this study. 
The study was approved by the Medical Ethical Committee of the University Hospital 
Rotterdam. 
STUDY DESIGN 
5-AminoJaevuJinic acid administration 
Patients were randomized to varying time intervals to undergo an endoscopy with biop-
sies after ingesting 60 mg/kg ALA (Fluka, Buchs, Switzerland, 60 mg/kg) dissolved in 
orange juice (10 ml) and about 30 ml of water for rinsing. At 1, 2, 7, 8 and 24 h, two 
patients at each time and at 3, 4, 5 and 6 h, 4 patients at each time after ALA inges-
tion were included. 
All patients were kept in a darkened room until 9 h after the ingestion of ALA and then 
left the hospital with an umbrella and sunglasses to protect them from ALA-induced skin 
and eye photosensitivity. Since we observed that the first patients participating in the 
study experienced skin photosensitivity, we advised the other patients to apply a sun-
screen with high UV protection (Nivea Sun® Sunblock 70, containing titanium dioxide, 
Beiersdorf AG, Hamburg, Germany) during their stay in the hospital and during their way 
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home. Photodegradation of porphyrins and photosensitisation tissue damage during 
exposure to the light of the endoscope was prevented by covering the light emitting part 
of the endoscope with an acrylate yellow filter (Wientjes B. V, Roden, The Netherlands). 
This filter eliminates nearly all UV and blue light below a wavelength of about 520 nm 
(Hinnen et al., 2000b). Side effects were monitored by interviews with the patients. 
Biopsy samples 
Apart from one patient, who was unable to undergo the endoscopy at the planned time 
because of vomiting, abdominal pain and diarrhea, all patients underwent an endoscopy 
at the randomized time with biopsies taken from BE, normal squamous epithelium (SO) 
and normal gastric cardia mucosa (GC). Biopsies were embedded in formalin, sectioned, 
and stained with hematoxylin and eosin. The grade of dysplasia in Barrett's mucosa was 
described according to Haggitt (Haggitt, 1994). In addition, adjacent biopsies were 
frozen (-70°C) for the determinations of ALA, porphobilinogen (PBG), uroporphyrin 
(URO) and PPIX. 
Blood and urine samples 
Blood samples were collected prior to and at 0.5, 1, 2, 4, 6 and 8 h after the adminis-
tration of ALA. Whole blood was collected in heparinized tubes wrapped in aluminum foil 
to prevent photoconversion and photodamage, and kept on ice. The blood samples were 
centrifuged at 1300 x g for 10 minutes, then the plasma was removed, protected from 
light and stored at -70°C for the determination of ALA, PBG, URO and PPIX. 
Some 24 h after the administration of ALA, an early morning urine sample was collected 
by the patient and sent to the laboratory for the determination of ALA, PBG and URO. 
LABORATORY ASSAYS 
Chemicals 
PPIX disodium salt, zinc PPIX and PBG were obtained from Porphyrin Products (Logan, 
UT, USA). Coproporphyrin, URO and Triton X -100 were obtained from Sigma Chemical 
Co. (St. Louis, MO, USA). Tris-HCL was obtained from Boehringer Mannheim (Mannheim, 
Germany). All other chemicals were obtained from Merck (Darmstadt, Germany). 
Determinations of ALA, PBG, URO and PPIX in plasma, tissue and urine 
Determinations of ALA and PBG in plasma, tissue and urine and determinations of por-
phyrins in urine were performed as described previously (van den Boogert et al., 1998). 
Urine concentrations were expressed in ~moljmmol creatinine. 
URO was extracted from 25 ~I tissue homogenate or plasma (twofold diluted in NaCI 
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(150 mmol/L)) by addition of 200 ~I of URO extraction buffer (Tris-HCI 50 mmol/L, pH 
8.0; trichloroacetic acid, 1.5 mol/L in aqua dest., (3/5, v/v)). After 5 minutes exposure 
to UV light (350 nm), to convert porphyrinogens into porphyrins, the samples were cen-
trifuged for 7 minutes at 3000 x g. The fluorescence of the supernatant was measured 
at an excitation wavelength of 410 nm and an emission wavelength of 656 nm using a 
LS 50B spectrofluorometer with a red sensitive photomultiplier (Perkin Elmer, 
Nieuwerkerk aid IJssel, The Netherlands). Values were calculated according to a standard 
curve of URO I in URO extraction buffer. Recovery of porphyrins during the extraction 
was determined by adding standard URO to the samples and recoveries were found in 
the range of 85-100%. 
PPIX was extracted from tissue by adding 50 ~I PPIX extraction buffer (Tris-HCI 50 
mmol/L, pH 8.0; 425 ~I dimethylsulfoxide/methanol, (DMSO/MeOH, 30/70, v/v)) to 
25 ~I tissue homogenate. The diluted homogenate was mixed vigorously using a vortex 
and left for about 30 minutes at room temperature. Samples were then centrifuged for 
10 minutes at 3000 x g. One-hundred ~I of supernatant was injected on a HPLC as 
described preViously (van Hillegersberg et al., 1992), however using an excitation wave-
length of 415 nm and an emission wavelength of 630 nm. For the extraction of PPIX 
from plasma, 950 ~I of PPIX extraction buffer was added to 50 ~I plasma. Values were 
calculated according to standard curves of Zinc-PPIX and PPIX in DMSO/MeOH (30/70, 
v/v). Recovery of porphyrins during the extraction was determined by adding standard 
Zinc-PPIX and PPIX to the samples and recoveries were found in the range of 90-100%. 
Plasma levels were expressed in nmol/L and tissue levels in pmol/mg protein. Tissue con-
centrations were also calculated in nmol/L for comparisons with plasma concentrations. 
STATISTICAL ANALYSIS 
Data are expressed as means ± sem. The analysis of statistical significance was performed 
using the Wilcoxon signed-rank test or the Wilcoxon rank-sum test for within, respec-
tively, between patients comparisons. For the determination of the time interval at which 
maximum PPIX concentrations were found in the different tissues, and the maximum 
concentration itself, a piece-wise linear model was used (Neter and Wasserman, 1974). 
In this analysis, the PPIX concentrations were logarithmically transformed. From the plas-
ma ALA concentrations of the individual patients, the ALA concentration in plasma at 
the time of biopsy of each patient was calculated. To determine the standard errors and 
the statistical significant differences between times of maximal concentrations in the dif-
ferent tissues, the bootstrap method was used (Efron and Tibshirani, 1993). To study pos-
sible correlations, Spearman correlation coefficients were calculated or linear regression 
analyses were performed. Two-sided P-values <0.05 were considered significant. 
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Results 
PPIX was the main metabolite of ALA found in tissue and plasma samples. Since the 
concentration of URO was very low compared to PPIX in both tissue and plasma sam-
ples, the URO data were omitted from further analysis. No porphyrins were detected in 
plasma samples before the administration of ALA (FIGURE 2). 
ALA (~moI/L) BE 
20000 
10000 
o 2 4 6 
ALA (~moIfL) plasma 
1000 
500 
8 hours 10 
FIGURE 2 Pharmacokinetics of 5-aminolevulinic acid (ALA) in tissue ( ... ) and plasma (0) of patients 
with Barrett's oesophagus (BE) after ingestion of 60 mg/kg AL4. Concentrations (IJmol/L) in 
means ± sem; BE, n=2 at 1, 2, 7 and 8 h, n=4 at 3, 4, 5 and 6 h; plasma n=26 at all Ume inter-
vals. Please note the different axes for BE and plasma and the 20-fold difference at 1 hour between 
the tissue and plasma ALA concentrations. 
PPIX CONCENTRATIONS IN TISSUES 
Maximum concentrations of PPIX after ALA ingestion were found at different time inter-
vals (mean ± sem) in the various tissue types (FIGURE 3). The maximum concentration of 
PPIX was found earlier in BE (4.6 ± 0.5 h) than in SO (6.6 ± 2.2 h) (p<0.05, 95% con-
fidence interval for the time difference: 0.1 - 4.4 h, FIGURE 3). In Ge, the maximum con-
centration of PPIX was found at 4.8 ± 1.0 h. 
The maximum concentration was 122 pmol/mg protein in BE, 136 pmol/mg protein in 
SO and 117 pmol/mg protein in Gc. At all time intervals before the maximum concen-
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tration of PPIX was found in BE (t ~ 1, 2, 3 and 4 h, n~11), the concentration of PPIX in 
BE was not different from the PPIX concentration in 50 (p~O,86), At longer time inter-
vals after ALA ingestion (~5, 6, 7, 8 and 24 h, n~14), the PPIX concentration was sig-
nificantly lower in BE compared to 50 (p~O,013), The longer the time interval after ALA 
ingestion, the greater the difference between the PPIX concentrations in BE and 50 
(p<O,001) , 
PLASMA ALA VERSUS TISSUE ALA CONCENTRATIONS 
At 1 hour after ALA ingestion, the intracellular ALA concentration was about 20 times 
higher in all types of tissue than in plasma, The pharmacokinetics of ALA in BE and plas-
ma is shown as a time course in FIGURE 2, After 1 hour, tissue concentrations of ALA rap-
idly decreased and at 2-8 hand 24 h, tissue ALA concentrations were not significantly 
different from plasma ALA concentrations (p~0.26), 
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FIGURE 3 Protoporphyrin IX (PPIX) kinetics in tissues of 26 patients with Barrett's oesophagus after 
ingestion of 5-aminolevulinic a6d (ALA) (60 mg/kg). Peak PPIX levels occur at a significantly earlier 
time point in BE (-) than in SQ (---) (4,6 ± 05 versus 6,6 ± 2.2 hours, p<O,05, piece-wise linear model) 
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PHARMACOKINETICS OF 5-AMINOLAEVULINIC ACID, PORPHOBILINOGEN AND 
PROTOPORPHYRIN IX IN PLASMA 
Maximum plasma concentrations of ALA (898 ± 45 ~mol/L, mean ± sem) were found 
at 1 hour after ALA ingestion in all patients (FIGURE 2). After the initial absorption and 
distribution phase the ALA concentration decreased significantly and followed first-order 
kinetics with a mean half-life of 13 ± 0.1 h (range: 0.7 -1.9 h). At 8 h, the plasma ALA 
concentration had returned to base-line levels. At 6 h, maximum plasma concentrations 
of PBG (20 ± 1 ~mol/L) and PPIX (942 ± 129 nmol/L) were found. 
ALA IN URINE 
At 24 h after ALA ingestion. the urine concentration of ALA was found in the normal 
range in 21 patients (4.1 ± 0.9 ~mol ALA/mmol creatinine). However, in 5 patients the 
concentration of ALA in urine after 24 h was still above the normal range (152.7 ± 20.7). 
In all 26 patients the plasma ALA concentrations found at 1 hour after ALA ingestion 
correlated with urine ALA concentrations found at 24 h (Spearman, p=0.02) The five 
patients with high urine ALA concentrations at 24 h appeared to have a significantly high-
er plasma ALA concentration at 1 hour after ALA ingestion than the patients with nor-
mal urine ALA concentrations at 24 h (1100 ~mol/L versus 815 ~mol/L. p=0.015). 
However, the decrease in plasma ALA concentrations was not different between the two 
groups (high or low ALA concentration in urine, p=0.82). 
SIDE EFFECTS 
The most common side effect was skin photosensitivity. During the first 9 h after ALA 
administration. 9 of 26 patients (35%) developed painful erythema of the facial skin. The 
next day, another 11 patients (42%) complained of redness and painful sensations in 
their face. In 5 of 20 patients (25%) with skin photosensitivity. the erythema was accom-
panied by edema. i.e .. around the eyes. One of these patients also had severe edema of 
his hands. The painful sensations subsided within 48 h and erythema within a few days 
after ALA ingestion. 
One patient had severe abdominal cramps accompanied by vomiting and diarrhoea from 
45 until 10 h after ALA ingestion and was therefore not subjected to an endoscopy. Two 
other patients also vomited after ALA ingestion, one at 5 h and the other at 9 h after 
ALA administration. 
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Discussion 
Knowledge of the pharmacokinetics of ALA and ALA-induced PPIX in BE and surrounding 
normal tissues could help to optimize treatment parameters such as the interval between 
administration of ALA and illumination. Up to now, accumulation of PPIX in these tissues 
has only been quantified by fluorescence microscopy (Barr et al., 1996; Regula et al., 1995). 
We previously determined the intracellular concentrations of ALA and PPIX in tissues of 
patients with BE (Hinnen et al., 2000a). There appeared to be no selectivity in the accu-
mulation of PPIX in BE compared to SQ at a mean time interval of 6.7 h after ALA inges-
tion. However, we found evidence that the rate of porphyrin biosynthesis was higher in BE 
compared with SQ. 
In view of this, we hypothesized that maximum PPIX concentrations could be reached at an 
earlier time in BE than in SQ. In the present study, we confirmed that maximum PPIX con-
centrations occurred at a significantly earlier time point in BE than in SQ (4.6 versus 6.6 h, 
FIGURE 3). After the time that the maximum PPIX concentration was found in BE, PPIX con-
centrations in biopsies from SQ became significantly higher compared with BE. It was 
shown that the difference in PPIX concentrations between SQ and BE was greater at longer 
time intervals after ALA ingestion. A selective PDT effect can therefore only be achieved by 
local illumination of the Barrett's epithelium as this study emphasizes the fact that selectiv-
ity in PPIX accumulation lies not in the difference between the accumulation of PPIX in BE 
and SQ (Hinnen et al., 2000a), but in the difference between the accumulation in mucosa 
and underlying muscle as has been demonstrated in recent studies (Barr et al., 1996; van 
den Boogert et al., 1999). Since squamous mucosa builds up significantly higher levels of 
PPIX at longer time intervals than BE, unwanted photodamage to SQ will be reduced when 
PDT is performed early within the time window, i.e. at 4-5 hours after ALA administration. 
So far, PPIX has only been quantified by biochemical extraction methods in one other study 
(Ackroyd et al., 1999). In that study biopsies were taken at 2, 4 and 6 hours after ALA 
ingestion. The authors suggested that peak levels of PPIX occured at 4 hours after ALA 
administration in normal oesophageal tissue and at 6 hours after ALA administration in 
Barrett's mucosa. In our opinion, maximum concentrations of PPIX and the time interval at 
which this concentration is reached can not be accurately calculated from only three time 
intervals as levels at earlier and later time intervals were not determined in that study. 
At 1 hour after ALA ingestion, concentrations of ALA in BE, SQ and GC were found to be 
20-fold higher than the concentrations in plasma at that time. Only two patients were 
included at that time interval, but as levels were very high at that time they could be meas-
ured with great accuracy. This phenomenon suggests local absorption of ALA at the lumi-
nal site of oesophageal and gastric tissues. The acidic environment of orange juice, in which 
ALA was dissolved, leaves a part of the ALA molecules uncharged. This may have facilitat-
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ed direct absorption (passive diffusion) of ALA by the epithelial cells. Local absorption of 
ALA under acidic conditions by passive diffusion is an advantage in the treatment of skin 
and bladder abnormalities with ALA-PDT (Kennedy and Pottier, 1992; Kriegmair et al., 
1996). In contrast to ALA, the tissue concentrations of PBG and PPIX never reached such 
high levels. This might be due to the fact that the cells were overloaded with ALA for only 
a short period of time. This is supported by the fact that tissue ALA concentrations 
decreased rapidly from 1 hour to equal plasma concentrations at 2-8 h. Our findings pro-
vide support for the concept that local use of ALA in the oesophagus might be advanta-
geous. By this approach, the cellular heme biosynthetic pathway could be overloaded with 
ALA for a longer exposition time. Application of ALA in a gel or a spray has been used by 
Vonarx et al. in mice (Vonarx et al., 1997) and by Ortner et al. (Ortner et al., 1997) in 
patients. This may possibly induce an even higher local PPIX accumulation in the exposed 
tissue. 
The optimism about negligible photosensitivity of the skin after ALA (Barr et al., 1996; 
Gossner et al., 1998) was not confirmed by our study. Thirty-five percent of our patients 
developed painfull erythema of their facial skin already during the first 9 h after adminis-
tration of ALA and being kept in a room with subdued light. In total, 77% of the patients 
developed skin photosensitivity. Additional preventive measures such as the application of 
sunscreen protection factor 70 did not prevent the symptoms of photosensitivity. Moreover, 
one should also be aware that exogenous ALA might provoke porphyria-like symptoms as 
was demonstrated by one patient in our study. 
As we demonstrated rapid kinetics of ALA and PPIX in all patients, the abnormal concen-
trations of ALA in the urine samples of 5 patients (19%) were unexpected. Despite thor-
ough biochemical and clinical investigations which only revealed a higher ALA concentra-
tions in plasma at 1 hour after ALA administration, these patients were clinically and bio-
chemically not different from the other patients. 
In conclusion, this is the first study in which PPIX concentrations were determined at suffi-
cient time intervals in tissues and plasma of patients with BE after ALA ingestion to allow 
reliable pharmacokinetics of PPIX . Maximum PPIX concentrations occured at a shorter time 
interval after ALA ingestion in BE than in SQ. Concentrations of PPIX were higher in SQ 
especially at longer time intervals. In addition, tissue ALA concentrations were found to be 
20-fold higher than the plasma concentrations at 1 hour after ALA ingestion. Side effects, 
i.e., skin photosensitivity is short-lasting but can be serious. These results provide a biolog-
ical rationale for the use of ALA-PDT for the treatment of BE at 4-5 h after ALA ingestion 
(60 mg/kg) and for the local application of ALA in the oesophagus. 
Acknowledgements 
We thank Mr Jan van de Berg for his technical assistance. 
76 
Pharmacokinetics of ALA and PPIX in human Barrett's oesophagus 
References 
Ackroyd, R., Brown, N., Vernon, D., Roberts, D., Stephenson, T., Marcus,S., toddard, C and Reed, M., 5-
Aminolevulinic acid photosensitization of dysplastic Barrett's esophagus: a pharmacokinetic study. Photochem. 
Photobiol., 70. 656·662 (1999). 
Barr, H., Shepherd, N.A .. Dix, A., Roberts, D.J., Tan, W.C and Krasner, N., Eradication of high-grade dysplasia 
in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protopor-
phyrin IX. Lancet. 348, 584-5 (1996). 
Biddlestone, loR., Barham, c.P., Wilkinson, S.P., Barr, H. and Shepherd, N.A, The histopathology of treated 
Barrett's esophagus: squamous reeplthelialization after ac'ld suppression and laser and photodynamic therapy. 
Am J Surg Pathol, 22, 239-45 (1998). 
Bishop, D.E and Desnkk, R.J., Assays of the heme blosynthetic enzymes. Preface. Enzyme, 28, 91-3 (1982). 
Drewitz, D.J., Sampllner, R.E. and Garewal, H5., The incidence of adenocarcinoma in Barrett's esophagus: a 
prospective study of 170 patients followed 4.8 years. Am J Gastroenterol, 92, 212-5 (1997). 
Efron, B. and Tibshirani, R.J., Book: An introduction to the bootstrap, Chapman and Hall, london; Chapter 9, 
Regression models, p 105-21 (1993). 
Gossner, l., Stolte, M., Sroka, R., Rick, K., May, A, Hahn, E.G. and Ell, C, Photodynamic ablation of high-grade 
dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology, 114, 
448-55 (1998). 
Haggitt, R.C, Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol, 25, 982-93 (1994). 
Hameeteman, W., Tytgat, G.N., Houthoff, H.J. and van den Tweel, J.G., Barrett's esophagus: development of 
dysplasia and adenocarcinoma. Gastroenterology, 96, 1249-56 (1989). 
Hamilton, S.R. and Smith, R.R., The relationship between columnar epithelial dysplasia and invasive adenocar-
cinoma arising in Barrett's esophagus. Am J Clin Pathol, 87, 301-12 (1987). 
Hinnen, P., de Rooi], EW.M., Terlouw, E.M., Edixhoven, A, van Dekken, H., van Hillegersberg, R., Tilanus, 
H.W., Wilson, J.H.P. and 5!ersema, P.D., Porphyrin biosynthesis in human Barrett's oesophagus and adenocar-
cinoma after ingestion of 5-aminolaevulinic acid. Sr J Cancer, 83, 539-543 (2000a). 
Hinnen, P., de Rooij, F.W.M., Velthuysen van, M.l.E, Edixhoven, A, Hillegersberg van, R., Tllanus, H.W., 
Wilson, J.H.P. and Siersema, P.D., Biochemkal basis of 5-aminolaevulinic acid-induced protoporphyrin IX accu-
mulation: a study in patients with (pre)malignant lesions of the esophagus. Sr J Cancer, 78, 679-682 (1998). 
Hinnen, P., de Rooij, F.W.M., Voortman, G., Tilanus, H.W., Wilson, J.H.P. and Siersema, P.D., Acrylate yellow 
filters in operating lights protect against photosensitization flssue damage. Sr J Surg, 87, 231-235 (2000b). 
Kennedy, J.e. and Pottier, R.H., Endogenous protoporphyrin IX, a dinkally useful photosensitizer for photody-
namic therapy. J Photochem Photobiol B, 14, 275-92 (1992). 
Kriegmair, M., Baumgartner, R., Lumper, W., Waidelich, R. and Hofstetter, A., Early clinkal experience with 5-
aminolevulinic acid for the photodynamic therapy of superfkial bladder cancer. Br) Ural, 77, 667-71 (1996). 
loh, CS., Vernon, D., MacRo bert, AJ., Bedwell, J., Bown, S.G. and Brown, S.B., Endogenous porphyrin distri-
bution induced by 5-aminolaevulinic acid in the tissue layers of the gastrOintestinal tract. J Photochem 
Photobiol8, 20, 47·54 (1993). 
Neter, J. and Wasserman, W., Book: Applied linear statistical models, Irwin, R. D., inc., Homewood, Illinois 
(1974). 
77 
Chapter 5 
Ortner, M" Zumbusch, K., Liebetruth, J. t Ernst, H., Wirth, l.r Wedel, S. and Lochs, H., Photodynamic therapy 
of Sarrett's esophagus after local administration of 5-aminolaevulinic acid. Gastrointestinal Oncofogy, A633 
(1997). 
Regula, J' t MacRobert, A.J., Gorchein, A., Buonaccorsi, G.A., Thorpe, S.M., Spencer, G.M., Hatfield, A.R. and 
Bown, S.G. r Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours 
using 5 aminolaevulinic acid induced protoporphyrin IX-a pilot study. Gut, 36, 67-75 (1995). 
van den Baegert, l'r Houtsmuller, A.B., de Rooij, F.W., de Bruin, R.W., Siersema, P.O. and van HilJegersberg, 
R., Kinetics, loca!ization, and mechanism of 5-aminolevulinic add-induced porphyrin accumulation in normal 
and Barrett's-like rat esophagus. Lasers Surg Med, 24, 3-13 (1999). 
van den Boogert, 1., van Hillegersberg, R., de Rooij, F.W., de Bruin, R.W., Edixhoven-Bosdijk, A, Houtsmulier, 
AB., Siersema, P.O., Wilson, J.H. and Tilanus, H.W., 5-Aminolaevulinic acid-induced protoporphyrin [X accu-
mulation in tissues: pharmacokinetics after oral or intravenous administration. ) Photochem Photobiol B, 44, 
29-38 (1998). 
van der Burgh, A, Dees, J., Hop, w.e and van Blankenstein, M., Oesophageal cancer is an uncommon cause 
of death in patients with Barrett's oesophagus. Gut, 39, 5-8 (1996). 
van Hiliegersberg, R., Van den Berg, J.W., Kort, WJ., Terpstra, O.T. and Wilson, J.H., Selective accumulation 
of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology, 103, 647-51 
(1992). 
Vonarx, V., Eleouet, S., Carre, J., ross, P., Gouyette, A, Leray, AM., Merle, e, lajat, Y. and Patrice, T., Potential 
efficacy of a delta 5-aminolevulinic add bioadhesive gel formulation for the photodynamic treatment of lesions 
of the gastrOintestinal tract in mice.) Pharm Pharmacol, 49, 652-6 (1997). 
Winters, e, Spurling, T.1., Chobanian, S.J. and aI., e., Barrett's esophagus: a prevalent occult complication of 
gastroesophageal reflux disease. Gastroenterology, 92, 118-124 (1987). 
78 


1 2 3 4 5 7 8 9 10 
Ferrochelatase activity inhibition 
by 5-aminolaevulinic acid-induced 
photodynamic therapy. 
Submitted 
P. Hinnen, PD. Siersema, A. Edixhoven, JHP. Wilson, FWM. de Rooij 
Departments of Gastroenterology and lnternal Medicine, University Hospital Rotterdam-Dijkzigt, Dr. 
Molewaterplein 40, 3015 GO Rotterdam, The Netherlands. 
11 

---------- Ferrochelatase inhibition by ALA-PDT ----------
Abstract 
Administration of 5-aminolaevulinic acid (ALA) leads to porphyrin accumulation in 
tumour cells, mostly as protoporphyrin IX. ALA is used as a pro-drug for photodynamic 
therapy (ALA-PDT). The effect of ALA-PDT, using UV light and 633 nm laser light, on 
the activities of two haem biosynthetic enzymes porphobilinogen deaminase and fer-
rochelatase was studied in human EBV-transformed Iymphoblastoid cell lines as a model 
of human tumour cells. Ferrochelatase activity was significantly inhibited by ALA-PDT, 
whereas the porphobilinogen deaminase activity remained unchanged. The extent of fer-
rochelatase inhibition was related both to the intracellular protoporphyrin IX concentra-
tion and to the time of UV light exposure. ALA-PDT therefore causes a relative block in 
haem biosynthesis by inhibiting ferrochelatase. A short period of pre-illumination of ALA-
treated porphyrin-loaded tissues might enhance porphyrin accumulation and a second 
illumination might result in a more pronounced ALA-PDT effect. 
Introduction 
5-aminolaevulinic acid (ALA) induced porphyrin accumulation, which is predominantly 
protoporphyrin IX (PPIX), is used for ALA-based photodynamic therapy (ALA-PDT) 
(Kennedy and Pottier, 1992; Peng et al., 1997). During illumination of porphyrin- con-
taining tissues with light of an appropriate wavelength tissue destruction results through 
oxidative processes that affect specific cell structures adjacent to the production site of 
porphyrins (linuma et al., 1994; Moan, 1990; Weishaupt et al., 1976). 
It is of interest to follow the steps leading to the production of PPIX. Two molecules of 
ALA are converted to porphobilinogen, which is metabolised to porphyrinogen interme-
diates by porphobilinogen deaminase (PBG-D). The last step of the haem synthesis is the 
introduction of iron into PPIX, catalysed by ferrochelatase (FC). Exogenous ALA admin-
istration bypasses the first and rate-limiting step of porphyrin synthesis, catalysed by ALA-
synthase, and PBG-D then becomes the rate-limiting enzyme in haem formation (Bishop 
and Desnick, 1982). Both normal and tumour tissues accumulate porphyrins after admin-
istration of ALA (Kennedy and Pottier, 1992). However, in human tumours we have 
observed an increased ratio between the activities of PBG-D and Fe compared to normal 
tissues (Hinnen et al., 1998). The changed balance between these enzyme activities 
might contribute to a relative increase of porphyrin accumulation in these tissues com-
pared to normal tissues. 
ALA-PDT is at present being used in the treatment of several premalignant and malignant 
disorders (Peng et aI., 1997). However results in skin tumours and Barrett's oesophagus 
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suggest that ALA-PDT needs to be improved (Barr et al., 1996; Gossner et al., 1998). 
An option currently being explored to optimize ALA-PDT is to interfere in the haem 
biosynthetic pathway to increase the cellular PPIX concentration (Curnow et al., 1999; 
Gaullier et al., 1997; Tan et af., 1997). The mitochondrial enzyme FC is of especial inter-
est as during the insertion of iron into PPIX, it envelops PPIX. It has been demonstrated 
in vitro that the primary site of phototoxic damage by ALA-PDT is the mitochondrion 
(Iinuma et al., 1994; Liang et al., 1998; Peng et al., 1996). Considering the diffusion 
length of oxygen radicals formed during ALA-PDT (Moan, 1990) and the close interac-
tion between PPIX and FC, it is likely that FC will be more prone to photodamage than 
cytoplasmatic enzymes such as PBG-D. Illumination of porphyrin- containing cells shortly 
after starting incubation with ALA, might therefore damage FC and leave PBG-D intact, 
and could be a means of further increasing porphyrin levels for ALA-PDT. 
In this study we examined the effect of UV light (365 nm) and red laser light (633 nm) 
after ALA administration on both the FC and PBG-D activity in a human tumour cell 
model. We used human EBV-transformed Iymphoblasts as a tumour cell model. Two dif-
ferent light sources were used. Firstly, UV ligth as porphyrins have their absorption max-
imum at these wavelengths (the so-called S0ret band). Secondly, we used red laser light 
(633 nm), the weakest absorption band of porphyrins, however with deeper tissue pen-
etration then UV light and therefore better clinical properties. 
Materials and methods 
CHEMICALS 
RPMI-1640 medium and penicillin-streptomycin were supplied by Biowhittaker 
(Maryland, MD, USA) and fetal calf serum (FCS) by Gibco Laboratories (Grand Island, 
NY, USA). The following reagents were obtained from Porphyrin Products (Logan, UT, 
USA): PPIX disodium salt, zinc PPIX, uroporphyrin and porphobilinogen. ALA-HCI and 
Triton X-100 were purchased from Sigma Chemical Corporation (St. Louis, MO, USA). 
Tris-HCL was purchased from Boehringer Mannheim (Mannheim, Germany). All other 
reagents were of analytical grade and used as received. 
CELL LINES AND CULTURE CONDITIONS 
EBV-transformed human Iymphoblastoid cells of six healthy individuals were cultured in 
75 cm2 flasks (Costar, Corning Incorporated, Corning, NY, USA) at 3rC in a humidified 
atmosphere (5% CO2 in air) on RPMI-1640 medium supplemented with 15% heat-inac-
tivated FCS, 105 I.U.j1 penicillin and 100 mg/I streptomycin. 
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INCUBATION CONDITIONS 
Exponentially proliferating cells were harvested and used for the experiments. During the 
first series of experiments UV light used. In these experiments cells were resuspended in 
a medium containing NaCI (138 mmoIjL), Na2HP04 (8 mmoIjL), CaCl2 (1.0 mmoIjL), 
KCI (2.7 mmoIjL), KH2P04 (1.5 mmoljL) and MgCI (0.5 mmoIjL). In the second series 
of experiments, using red laser light, standard RPMI culture medium was used for prac-
tical reasons. To compensate the pH decrease due to ALA in the medium the pH was 
adjusted to 7.6 before the incubations. 
In pilot experiments, we found that the ability to accumulate porphyrins from ALA was 
the same in all cell lines (data not shown). 
ILLUMINATION EXPERIMENTS 
Genera! condWons 
Before and after illumination, samples of incubated cells were drawn and washed in 
saline (NaCi 150 mmoljL) by centrifugation at 55 x g, to remove ALA and to isolate the 
intact cells in the pellet. In addition the porphyrin concentration, the protein concentra-
tion and the activity of FC and PBG-D were determined. The FC and PBG-D activity of 
illuminated cells was expressed as a percentage relative to the activity of their non-illu-
minated controls (100 %). The effect of ALA or PPIX on FC and PBG-D activities of non-
illuminated cells and the effect of light exposure on FC and PBG-D in cells incubated in 
the absence of ALA was determined as controls in each experiment. 
UV light experiments 
Each cell line was incubated with 0.4 mmoljL ALA, and 19 samples were drawn at each 
time interval of 0, 30, 60 and 120 minutes. Subsequently, these samples were illuminat-
ed with UV light (365 nm, 7 mW/cm2) generated by a UV transilluminator L 2734 
(LabCenter, Breda, The Netherlands) for 0,2.5,5 or 10 minutes. Cell samples with a pro-
tein content below the level of the minimum protein standard were excluded from fur-
ther analysis. The intracellular porphyrin concentration, the protein concentration and the 
activity of FC were then determined. 
633 nm laser light expedments 
Cell lines were incubated in the presence of various ALA concentrations (0, 0.1, 0.2, 0.4, 
0.6,0.8 and 1.2 mmoljL) for 2 hours. Subsequently, cells were exposed for 125 seconds to 
633 nm laser light (100 mW/cm2) generated by a 600 Series Dye module pumped by a 
KTP /532 surgical laser (Laserscope, San Jose, CA, USA). The intracellular porphyrin concen-
tration, the protein concentration and the activity of FC and PBG-D were then determined. 
85 
Chapter 6 
FERROCHELATASE AND PORPHOBILINOGEN DEAMINASE ASSAYS AND PORPHYRIN 
ANALYSIS 
Ferrochelatase (FC) activity was measured by a modification of the method of Li et al. 
as described previously (Li et al., 1987; Van Hillegersberg et al., 1992). Cells were mixed 
with water and kept on ice before being used for the assay. 
Porphobilinogen deaminase (PBG-D) was measured as described previously (Hinnen et 
al., 1998; Wilson et al., 1986). The following adaptions were made; 
(a) One percent of bovine serum albumin (BSA) was added to the solution of porpho-
bilinogen in Tris-HCL buffer (pH 8.0) to prevent binding of enzyme molecules to the plas-
tic of the tubes.(b) The fluorescence of the supernatant, uroporphyrin-I, was measured at 
an excitation wavelength of 410 nm and an emission wavelength of 654 nm (Perkin Elmer 
LS 50B with a red sensitive photomultiplier, Perkin Elmer, Nieuwerkerk aid IJssel, The 
Netherlands).(c) Values were calculated according to a standard curve of uroporphyrin-I. 
Results of the FC and PBG-D activifles were expressed as pmols of porphyrins formed per 
mg protein per hour. 
PPIX accumulation was determined spectrofluorometrically (excitation wavelength: 417 
nm and emission wavelength: 636 nm) in the LS 50B spectrofluorometer. This result was 
divided by the protein content and expressed as arbitrary fluorescence units (F.U.). The 
protein content was determined according to the method of Lowry et al. (Lowry et al., 
1951). All experiments were performed in subdued light in duplicate. 
STATISTICAL ANALYSIS 
Data were expressed as means ± sem and analysed for statistical significance using the 
Student's t-test for paired values. Pearson correlation coefficients were calculated to study 
possible associations. Multiple regression analysis was used to examine the effect of the 
duration of exposure (min) to UV light and the intracellular porphyrin concentration on 
the activity of Fe. P-values <0.05 were considered significant. 
Results 
ALA or PPIX had no effect on enzyme activities in the dark and light exposure did not 
affect the activities of cells not incubated with ALA (FIGURE 1 and FIGURE 2). 
UV LIGHT EXPERIMENTS 
The Iymphoblastoid cells accumulated porphyrins linearly in relation to the incubation 
time (Pearson r ~ + 0.98, p < 0.001). In cells exposed to UV light, FC activity was inhib-
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ited and this inhibition was more pronounced at higher intracellular concentrations of 
porphyrins as well as after longer UV light exposure (FIGURE 1). The inhibition of FC 
depended on both the time of UV light exposure (p < 0.001) and the intracellular con-
centration of porphyrins (p ~ 0.001). Significant photoinactivation of FC by UV light was 
seen only with an illumination time of at least 5 minutes and with the porphyrin con-
centration that could be achieved by at least 60 minutes of incubation with ALA. 
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FIGURE 1 The effect of the time of exposure to UV light on ferrochelatase (FC) activity in six 
human EBV- transformed lymphoblast cell lines incubated with 0.4 mmol/L ALA. Cell lines incu-
bated for the same time period (min) and therefore with similar intracellular porphryin concentra-
tions were grouped and within these groups the effect of the time of exposure to UV light was 
stu&ed. Cell samples with a protein content below the level of the minimum protein standard were 
excluded from further analysis. The mean ± sem enzyme activity of illuminated cells was expressed 
as a percentage, relative to the activity of their non-illuminated controls (100%). *p5 0.001. 
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633 NM lASER LIGHT EXPERIMENTS: Fe ACTIVITY 
Fe activity of cells incubated with 0.6 mmol/L ALA for 2 hrs and subsequently illumi-
nated by 633 nm laser light was found significantly lower than that of non-illuminated 
controls (615 versus 750 pmol ZnPr/ mg protein/ hour; 82 ± 2% versus 100%, mean ± 
sem, n~22, p<0.001). When results of all incubations at all ALA concentrations were 
analysed, the activity of Fe was found to be inversely correlated to the intracellular por-
phyrin concentration (FIGURE 2, Pearson, P - 0.80, p<0.001). 
633 NM lASER LIGHT EXPERIMENTS: PBG-D ACTIVITY 
Illumination of cells following incubation with 0.6 mmol/L ALA for 2 hrs had no effect 
on the mean PBG-D activity. We found no difference in PBG-D activity compared to the 
non-illuminated controls (63.0±7.5 versus 63.7±6.5 pmol URO/ mg protein/hour, 100%, 
n~22). 
Fe activity C%) 
100 01 
• 
90 I 01 
r 
• 80
1 70 -, 
60 
50 -
40 -
-
: 
. · . 
. 
.: .. 
· . 
· . 
... 
· . 
. 
.. 
30 -_0- 00 __ --0 
o 500 1000 
F.U. 
•• ___ -_ .. 0 __ ' 
1500 2000 
FIGURE 2 The effect of red laser light (633 nm) on the activity offerrochelatase (FC) in six human 
EBV-transformed lymphoblast cell fines, used as a tumour cell mode!, incubated for 2 hours with 
various ALA concentrations (0, O. I, 0.2, 0.4, 0.6, 0.8 and 1.2 mM). The enzyme activity of illu-
minated cells waS expressed as a percentage, relative to the activity of their non-illuminated con-
trols (100%). Porphyrin concentrations are expressed as arbitrary fluorescence units (F.U.). 
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Discussion 
In this study, we investigated the effect of ALA-PDT on the activities of PBG-D and FC 
In view of the limited diffusion length of oxygen radicals produced during exposure of 
PPIX to light (Moan, 1990; Moan and Berg, 1991) and the moment of close interaction 
between Fe and PPIX (FC activity enholds the chelation of ferrous iron into PPIX), we 
expected the mitochondrial enzyme FC to be damaged during ALA-PDT, whereas cyto-
plasmic enzymes such as PBG-D would remain intact. In porphyrin- containing human 
EBV-transformed Iymphoblasts, used as a tumour cell model, we found that exposure of 
these cells to UV light and 633 nm laser light selectively damaged FC Photoinactivation 
of FC depended on both the concentration of cellular PPIX and on the time of exposure 
to UV light (FIGURE 1 and FIGURE 2). 
Apart from direct inactivation of FC, it is also possible that FC activity was decreased sec-
ondary to destruction of mitochondria since this organel is considered to be the primary 
target of ALA-PDT (Iinuma et al., 1994; Peng et al., 1996). However, in this study we 
found that human Iymphoblastoid cells were still able to accumulate PPIX after ALA-PDT 
when re-cultured in the presence of ALA. This suggests that direct inhibition of FC occurs 
even in the absence of mitochondrial destruction (data not shown). This is also support-
ed by studies of He et al., who found the same FC inhibiting effect of UV light, after cul-
turing A431 human epidermal carcinoma cells with ALA. The effect of UV light on FC 
was found to result from direct damage to FC, since mRNA levels of FC remained stable 
(He et al., 1995; He et al., 1993). lunima et al. found evidence that the subcellular local-
isation or even the submitochondrial localisation of PPIX might be important for the effi-
cacy of ALA-PDT. In two cell lines that differed in PDT-sensitivity despite containing equal 
amounts of PPIX, mainly located in the mitochondria, they found differences in submi-
tochondrial staining (Iinuma et al., 1994). 
As expected from its cytoplasmic localisation, PBG-D was not damaged by ALA-PDT. In 
contrast, Gibson et al. found an increased PBG-D activity after the administration of ALA 
in rat mammary adenocarcinoma (R3230 AC) and human mammary (MCF-7) and 
mesothelioma tumour cell lines (H-MESO-1) (Gibson et al., 1998). They suggested that 
ALA administration induced enzyme synthesis de novo. They administered cycloheximide 
to support this. However, cycloheximide inhibits the synthesis of all proteins and there-
fore also of regulatory proteins. As mRNA levels were not determined in that study it is 
not sure yet, whether PBG-D was induced de novo by the administration of ALA or that 
ALA only influenced the stability of the enzyme. In another study, Gibson et al. showed 
that the activity of PBG-D was inhibited by ALA-PDT in a rat mammary adenocarcinoma 
cell line (Gibson et al., 1999). Since kinetics of PPIX and factors influencing PPIX gener-
ation and PDT sensitivity can be different in different cell types, these factors might pos-
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sibly contribute to the conflicting findings (Wyld et al., 1997). 
In conclusion, ALA-PDT causes a relative block in haem biosynthesis by inhibiting Fe and 
sparing the activity of PBG-D. The ability of ALA-PDT pre-treated cells to accumulate por-
phyrins could be enhanced by two-phase ALA-PDT. A short period of pre-illumination of 
ALA-treated porphyrin-loaded Barrett's mucosa might enhance selective porphyrin accu-
mulation, resulting in a more pronounced ALA-PDT effect after a second illumination. 
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Abstract 
5-Aminolaevulinic acid-induced photodynamic therapy (ALA-PDT) is used for the treat-
ment of premalignant and malignant disorders. Excess exogenous ALA leads to intracel-
lular protoporphyrin IX (PPIX) accumulation. ALA-PDT by itself inhibits the activity of the 
haem biosynthetic enzyme ferrochelatase (Fe), which is responsible for the conversion of 
PPIX into haem. To examine the effect of ALA-PDT on PPIX accumulation and the effect 
of one or two laser treatments (two-phase ALA-PDT) on cell survival, we used EBV-trans-
formed Iymphoblastoid cells as a model of human tumour cells. ALA-treated cells were 
illuminated ones or twice with 633 nm laser light (100 mW/cm2 ) or kept in the dark 
for the same time period. At selected times, the porphyrin and protein concentrations 
were determined. Porphyrin biosynthesis remained intact in EBV-transformed Iym-
phoblastoid cells after a first episode of ALA-PDT. Following the first illumination, cells 
were able to accumulate significantly more PPIX than their non-illuminated controls. Two 
illuminations resulted in more cell death than one illumination. A two-phase illumination 
scheme may improve the clinical outcome of ALA-PDT. 
Introduction 
5-Aminolaevulinic acid-induced photodynamic therapy (ALA-PDT) is based on the con-
cept that the administration of ALA bypasses the rate-limiting enzyme of porphyrin syn-
thesis, ALA-synthase, and induces the accumulation of intracellular porphyrins, mostly 
protoporphyrin IX (PPIX) (Hinnen et al., 1999; Hinnen et aI., 2000; Hinnen et al., 1998; 
Kennedy and Pottier, 1992). After absorption of light by PPIX, energy is transferred to 
oxygen molecules (Weishaupt et al., 1976), leading to tissue destruction through oxida-
tive processes that affect cell structures adjacent to the production site of porphyrins 
(Iinuma et al., 1994; Moan, 1990). 
ALA-PDT is used clinically for certain skin lesions (Peng et al., 1997). For the treatment 
of Barrett's esophagus (Barr et al., 1996; Gossner et al., 1998), a pre-malignant lesion, 
and for colorectal neoplasms (Fromm et al., 1996; Mlkvy et al., 1995; Regula et al., 
1995) it is still in an experimental stage. The effects of ALA-PDT are heterogeneous; in 
Barrett's esophagus, the presence of islands of columnar cells remaining beneath regen-
erating squamous epithelium has created the concern that superficial healing could mask 
underlying dysplasia (Barr et al., 1996; Biddlestone et al., 1998).Therefore, ALA-PDT 
needs to be improved. 
In a previous study, using EBV-transformed Iymphoblastoid cell lines as a model of human 
tumour cells, we showed that ALA-PDT by itself caused a relative block in haem biosyn-
97 
Chapter 7 
thesis by inhibiting ferrochelatase, which catalyses the synthesis of haem by insertion of 
iron into PPIX (Hinnen et al., 1999). In addition, the activity of porphobilinogen deami-
nase remained unchanged after ALA-PDT. This enzyme was shown to be the rate-limit-
ing enzyme of haem biosynthesis after ALA synthase (Bishop and Desnick, 1982). 
An important factor influencing the efficacy of PDT is the concentration of photosensi-
tizer in the target tissue (iinuma et al., 1994; Tan et al., 1997). A method to increase the 
concentration of PPIX in tissues could be the use of a two-phase illumination schedule in 
which the first illumination is used to inhibit FC causing an increase in PPIX accumula-
tion and this could result in the second illumination to be more effective than only a sin-
gle illumination. In this study we examined the effect of ALA-PDT on PPIX accumulation 
and on cell survival after one or two illuminations in the EBV-transformed Iymphoblas-
toid cell line model. 
Materials and methods 
CHEMICALS 
RPMI-1640 medium and penicillin-streptomycin were supplied by Biowhittaker 
(Maryland, MD, USA) and fetal calf serum (FCS) by Gibco Laboratories (Grand Island, 
NY, USA). ALA-HCI, was purchased from Sigma Chemical Corporation (St. Louis, MO, 
USA) and Tris-HCL from Boehringer Mannheim (Mannheim, Germany). All other 
reagents were of analytical grade and used as received. 
CELL LINES AND CULTURE CONDITIONS 
Human EBV-transformed Iymphoblastoid cell lines of five healthy individuals were cul-
tured in 75 cm2 flasks (Costar, Corning Incorporated, Corning, NY, USA) at 37°C in a 
humidified atmosphere (5% C02 in air) on RPMI-1640 medium supplemented with 15% 
heat-inactivated FCS, 105 I.U.j1 penicillin and 100 mg/I streptomycin. Exponentially pro-
liferating cells were harvested, resuspended in fresh medium and incubated with or with-
out 0.6 mM ALA. To compensate the pH decrease due to ALA in the medium the pH 
was adjusted to 7.6. 
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INCUBATION AND ILLUMINATION EXPERIMENTS 
General conditions 
Four different illumination experiments (I, II, III, IV) were performed using 633 nm laser 
light (Laser-series, L cells) together with control experiments using an equal time period 
in the dark (Dark-series, D cells) (FIGURE 1). Apart from the laser treatment, all cells were 
incubated in the dark at 37oC. Cells incubated with ALA were exposed to 0.6 mM ALA. 
At selected times, cells were washed with NaCI solution (150 mM) and centrifugated at 
55 x g to remove culture medium and ALA. For porphyrin determinations the cell pellets 
were resuspended in 1 ml NaCi (150 mM) and samples of 150 ~I were drawn. 
Subsequently, the cell suspensions were centrifugated at 55 x g and the cell pellets were 
resuspended in 110 ~I aqua dest. for protein determinations. 
The laser treatment consisted of an exposure time of 125 s to 633 nm laser light (100 
mW/cm2) generated by a Dye module pumped by a KTP/532 surgical laser (Laserscope 
UK Ltd, Gwent, UK). 
Experiments 
All experiments started with an incubation period of 2 h in the presence of ALA (L 1 -7 
L2 or D1 -7 D2 in FIGURE 1) followed by a laser or dark treatment (L3, D3). 
Experiment I and II: The effect of two courses of ALA-PDT followed by incubation in 
medium containing ALA (Exp. I) or in medium without ALA (Exp. II) on porphyrin con-
centration and cell death. After the initial PDT treatment, cells were re-incubated with 
ALA (Exp. I) or without ALA (Exp. II) for 3 h, then washed and subjected to a second 
laser treatment and again re-incubated with ALA (Exp. I) or without ALA (Exp. II) for 
another 17 h (Exp. I: D/L3 -7 D/L4a -7 D/L6a, Exp. II: D/L3 -7 D/L4b -7 D/L6b). 
Experiment III and IV: The effect of a single course of ALA-PDT followed by incubation 
in medium containing ALA (Exp. III) or without ALA (Exp. IV) on porphyrin concentra-
tion and cell death. After the initial PDT treatment, cells were re-incubated in medium 
with ALA (Exp. III) or without ALA (Exp. IV) for 20 h (Exp. III: D/L3 -7 D/L5a, Exp. IV: 
D/L3 -7 D/L5b). 
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FIGURE 1 Flow chart of experiments I, II, 1/1 and IV to study the effed of (two-phase) ALA-PDT on 
PPIX accumulation and cell death in cultured EBV-transformed Iymphoblastoid cells. The different 
experiments are explained in detail in the Matedals and Methods section. Laser series; 1255, 633 
nm, 100 mW/cm2 (f); arrow, with 0.6 mM ALA; dashed arrow, without ALA (control) 
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PORPHYRIN ANALYSIS AND PROTEIN DETERMINATION 
PPIX accumulation was determined spectrofluorometrically at an excitation wavelength of 
417 nm and an emission wavelength of 636 nm in a LS50B spectrofluorometer with a red 
sensitive photo multiplier (Perkin Elmer, Nieuwerkerk aid IJssel, The Netherlands). Porphyrin 
emission was expressed as mg of protein. After the first 2 h incubation period (D2, L2), the 
resulting porphyrin concentration was set at 100%. The porphyrin content of D and L cells 
was expressed as a percentage of the concentration in D2 and L2 cells, respectively. 
The protein content was determined according to the method of Lowry et at. (LOWry et 
at., 1951). In this study we used the protein content in the cell pellet as a measure of cell 
death. In all experiments it was observed that the protein content had not changed after 
the first illumination with 633 nm laser light or an equal time period in the dark. We 
therefore chose to set the protein contents of the D3 and L3 cells at 0%, suggesting that 
cell death and/or cell loss was not apparent at this time point. As a consequence, the 
protein content of D and L cells was expressed as a percentage of the protein content of 
the D3 and L3 cells, respectively. 
STATISTICAL ANALYSIS 
Data are expressed as means ± sem and were analysed for statistical significance using 
the Student's t -test for paired values. P-values <0.05 were considered significant. 
Results 
The effect of ALA-PDT (Laser-series) on the ability of human Iymphoblastoid cells to accu-
mulate porphyrins and the efficacy of one or two laser treatments is shown in TABLE 1. 
Results of statistical comparisons within and between the Laser- and Dark-series are 
shown in TABLE 2. 
The presence of ALA or PPIX had no effect on the survival of non-illuminated cells and 
light exposure did not affect the survival of cells incubated without ALA (TABLE 2). Cell 
loss in the Dark-series starting from D4a/D4b, is most likely the result of loss of cells due 
to the washing procedures. As a substantial amount of cells was lost due to handling dur-
ing the experiments, together with the individual spread in cell loss per experiment, we 
decided to compare means of groups of repeated light and dark experiments. 
During exposure of ALA-treated cells to 633 nm laser light, the intracellular concentra-
tion of porphyrins per mg protein decreased from 100% to 57% (L2 -7 L3, p<0.001), 
whereas porphyrin concentration did not change when ALA-treated cells were kept in the 
dark (D2 -7 D3). Immediate cell death after ALA-PDT was not observed (L2 -7 L3). The 
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percentage of cell death (and cell loss due to the washing procedure) after a single laser 
treatment (Exp. I and III) was found to be 66% after 3 h of re-incubation with or with-
out ALA (L3 -7 L4a/b) and this increased up to 80% after 20 h of re-incubation with or 
without ALA (L3 -7 L5a/b). More cells had died after 20 h than after 3 h of incubation 
(L4a/L4b vs L5a/L5b, p < 0.001). In addition, more cell death was found after two laser 
treatments than after one (L2 -7 L6a vs L2 -7 L5a, p < 0.001). When cultured without 
further ALA, all cells showed a significant decrease in porphyrins from 100% to unde-
tectable levels (Exp. II and IV of the Dark- and Laser-series). An additional period of 3 h 
re-incubation with ALA after a first course of ALA-PDT resulted in higher porphyrin levels 
in comparison to cells which had not been exposed to laser light (L4a vs D4a, p < 0.001). 
When cells were cultured with ALA for 20 h after the initial course of ALA-PDT, the por-
phyrin concentrations increased from 100% to 220% (L2 -7 L5a, p ~ 0.001), whereas por-
phyrin concentrations decreased from 100% to 55% in their non-illuminated controls (D2 
-7 D5a, p < 0.001). Porphyrin contents could not be determined in the cells that were 
treated twice by the laser as only a few cells survived and the protein content was far 
below the lowest standard (L6a). 
TABLE 1 The effed of ALA-PDT or darkness on the percentage of cell loss, cell death and intra-
cellular porphyrins in human fBV-transformed Iymphoblastoid cell lines. 
Dark- n cell loss porphyrin Laser n cell loss porphyrin 
seriesd (%) concentration serieSl & death concentration 
(%) (%) (%) 
D1 23 0 NDb L1 23 0 ND 
D2 23 0 100 L2 23 0 100 
D3 23 0 100 L3 23 0 57 ± 2 
D4a 23 33 ± 3d 110 ± 7 L4a 23 66 ± 3 119 ± 12 
D4b 18 32 ± 3 ND L4b 18 68 ± 3 ND 
D5a 23 36 ± 2 55 ± 5 L5a 23 80 ± 2 220 ± 30 
D5b 21 35 ± 2 ND L5b 21 77 ± 2 ND 
D6a 18 54 ± 2 46 ± 4 L6a 18 97 ± 1 NRC 
D6b 17 55 ± 2 ND L6b 17 87 ± 1 ND 
J See FIGURE 1 for the different experiments b NO, not detectable 
C NR, not reliable due to a too low protein content d means ± SE 
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TABLE 2 Comparisons between ALA-PDT and darkness effects on cell loss, cell death and porphyrin 
concentration in human EBV-transformed lymphobJastoid cell lines. 
Oark- cell loss porphyrin Laser cell loss porphyrin 
seriesil concentration seriesil & death concentration 
D2 vs D3 NSb NS L2 vs L3 NS P < 0.001 
D2 vs D4a p < 0.001 NS L2 vs L4a p < 0.001 NS 
D2 vs D5a p < 0.001 P < 0.001 L2 vs L5a p < 0.001 P ~ 0.001 
D2 vs D6a p < 0.001 P < 0.001 L2 vs L6a p < 0.001 
D4a vs D4b NS P < 0.001 L4a vs L4b NS P < 0.001 
D4a vs D5a NS p < 0.001 L4a vs L5a p < 0.001 P < 0.01 
D4a vs D6a p < 0.001 P < 0.001 L4a vs L6a p < 0.001 
D5a vs D5b NS P < 0.001 L5a vs L5b NS P < 0.001 
D5a vs D6a p < 0.001 NS L5a vs L6a p < 0.001 NS 
D6a vs D6b NS P < 0.001 L6a vs L6b p < 0.001 
L vs 0 cell loss porphyrin L vs 0 cell loss porphyrin 
concentration concentration 
L3 vs D3 NS P < 0.001 L5a vs D5a p < 0.001 P < 0.001 
L4a vs D4a p < 0.001 P < 0.001 L6a vs D6a p < 0.001 
a See FIGURE 1 for the different experiments 
b NS, not statistically significant 
Discussion 
Cultured human EBV-transformed Iymphoblastoid cells were used as a model of human 
tumour cells to study the effect of ALA-PDT on porphyrin accumulation and the effect 
of one or two laser treatments (two-phase ALA-PDT) on cell survival. In a previous study 
we used the same cell model and demonstrated that these cells accumulated porphyrins 
after the administration of ALA and that ALA-PDT (UV and 633 nm laser light) caused 
a relative block in haem biosynthesis by inhibiting Fe (Hinnen et al., 1999). He et a!. 
demonstrated that the inhibition of Fe activity in a human epidermoid carcinoma cell 
line resulted from direct damage to Fe since mRNA levels of FC remained stable. They 
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also found that re-incubation with ALA, following UV light exposure, resulted in an 
increase in PPIX accumulation (He et al., 1995; He et al., 1993). 
In this study, it was shown that illumination with red laser light (633 nm) had an imme-
diate effect on the intracellular porphyrin concentration, which significantly dropped 
from 100 % to 57 % (L2 --'> L3, FIGURE 1 and TABLE 2). After ALA-PDT, part of the haem 
biosynthetic pathway remained intact as cells were still able to accumulate porphyrins (L2 
--'> L4a and L5a). The FC inhibiting effect of ALA-PDT increased the accumulation of PPIX 
from newly administered ALA as was shown by significantly different intracellular por-
phyrin concentrations in the L4a and L5a cells compared to their non-illuminated controls 
(D4a and D5a). The finding that ALA-PDT increased PPIX accumulation, at least in part 
through FC inhibition, was further supported by the finding that the intracellular por-
phyrin concentration in non-illuminated cells dropped from 100% to 55% during 20 h of 
subsequent incubation with ALA (02 --'> D5a). We previously demonstrated that FC 
activity remained unchanged in these non-illuminated cells (Hinnen et al., 1999). As PPIX 
was not detectable in the medium (results not shown), the decrease in porphyrins sug-
gests that these cells were able to convert porphyrins into haem during the 20 h of re-
incubation. This was also supported by the finding that porphyrin concentrations in por-
phyrin-loaded cells in the second and fourth experiment of the Dark- and Laser-series 
decreased to undetectable levels after 3 h of re-incubation without ALA. 
In contrast to the instant decrease in intracellular porphyrins follOWing ALA-PDT, cell 
death was first detected at 3 h (arbitrary second sampling time) after the laser treatment. 
Cell death increased in time and was significantly higher after two laser treatments than 
after a single laser treatment. Direct cytotoxicity has been shown to be insufficient to 
explain the effects of PDT. Cells from murine tumours remaining in situ after PDT under-
go necrosis, whereas those explanted immediately after PDT remain viable in vitro 
(Henderson et al., 1985). This suggests that local tissue factors, for instance an effect on 
microcirculation (oxygen supply) (Leveckis et al., 1995) and/or the presence of neu-
trophils may play an important role (de Vree et al., 1996). In this study we only used the 
protein content as a measure of cell survival and local tissue factors were not present, 
possibly explaining the delayed process of cell death in the cultured cells studied. 
Previously, van der Veen et al. reported immediate photobleaching of PPIX after PDT and 
re-appearance of fluorescence in a transplantable rat mammary tumour model (van der 
Veen et al., 1994). As an explanation for this observation they suggested the occurrence 
of inhibition of Fe after illumination (He et al., 1993) or the release of PPIX from dam-
aged cells. In another study, these authors observed an improvement of the effect of 
ALA-PDT, in terms of an increased tumour volume doubling time of transplanted rat rab-
domyosarcoma, using a light fractionation time interval of 75 min (de Bruijn et al., 
1999). They proposed that new PPIX was formed during the interval of 75 min enhanc-
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ing the effect of the second illumination. The mechanism of the re-appearance of PPIX 
fluorescence may indeed be related to the decreased FC activity in cells after a single 
treatment. The decrease in FC activity caused by the initial course of ALA-PDT reduces 
the conversion of PPIX into haem, increases the accumulation of PPIX and provides an 
explanation for the increased PDT effect after two illuminations. In conclusion, our results 
strongly suggest that the haem biosynthetic pathway remains intact after ALA-PDT and 
that ALA-PDT enhances the ability of human EBV-transformed Iymphoblastoid cells to 
accumulate PPIX. This can at least in part be explained by the inhibiting effect of ALA-
PDT on the activity of Fe. This effect of ALA-PDT on FC activity (He et al., 1995; He et 
al., 1993; Hinnen et al., 1999) supports the observations that the primary target of ALA-
PDT is the mitochondrion (Iinuma et al., 1994; Liang et al., 1998; Peng et al., 1996). In 
addition the latter makes it unlikely that ALA-PDT interferes in haem biosynthesis by 
inhibiting the cytoplasmatic enzyme PBG-D as suggested by Gibson et al. (Gibson et al., 
1999). Cell death becomes apparent after some hours and the effect of PDT in terms of 
cell death is significantly better after two laser treatments than after a single treatment. 
Two-phase ALA-PDT may therefore be of clinical value in the efficacy of the treatment of 
malignant and pre-malignant disorders like Barrett's oesophagus. A local first phase of illu-
mination of Barrett's mucosa, following oral ingestion of ALA, might induce damage to 
Fe. As continuous influx of ALA from plasma exists, these illuminated cells will accumu-
late greater amounts of porphyrins compared with normal surrounding cells. Subse-
quently, a second phase of illumination may result in a more complete and selective abla-
tion and therefore improve the results of ALA-PDT for the treatment of disorders such as 
Barrett's oesophagus. 
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General discussion 
As stated in the introduction (chapter 1), the aim of this thesis was to study porphyrin 
and haem biosynthesis in (pre)malignant tissues of the human oesophagus before and 
after the administration of 5-aminolaevulinic acid (ALA). Two haem biosynthetic 
enzymes, porphobilinogen deaminase and ferrochelatase, are studied in more detail for 
their crucial role respectively in the secondary regulation of haem synthesis and the for-
mation of PPIX. 
I. PORPHOBILINOGEN DEAMINASE AND FERROCHELATASE ACTIVITIES IN HUMAN 
(PRE)MALIGNANT CELLS: DO THEY PREDICT PORPHYRIN ACCUMULATION? 
There are a limited number of publications about the activities of the two haem biosyn-
thetic enzymes porphobilinogen deaminase (PBG-D) and ferrochelatase (Fe) in normal as 
well as in (pre)malignant tissues. Increased PBG-D activity relative to normal tissue has 
consistently been found in tumours (el-Sharabasy et al., 1992; Navone et al., 1990; 
Schoenfeld et al., 1988) as well as in rapidly dividing cells, such as regenerating liver cells 
(Schoenfeld et al., 1988; Schoenfeld et al., 1987) suggesting that this phenomenon 
might be common in situations of increased cell replication. In contrast with the consis-
tent studies concerning the activity of PBG-D, there seems to be a difference in FC activ-
ity among different tumour types (Dailey and Smith, 1984; el-Sharabasy et al., 1992; 
Rubino and Rasetti, 1966; Smith, 1987; van Hillegersberg et al., 1992). In this thesis the 
main theme is the activities of PBG-D and FC in different tissues, as these activities prob-
ably play an important role in determining the rate of PPIX synthesis and accumulation 
after ALA administration. We were the first to measure these activities in human normal 
oesophageal (SQ) and gastric mucosa, Barrett's epithelium (BE) and adenocarcinoma of 
the oesophagus (Ae) (Chapters 2 and 4) (Hinnen et al., 2000a; Hinnen et al., 1998). 
The concept that the ratio between these enzyme activities would predict PPIX accumu-
lation in tissue after ALA administration was appealing. This would mean that patients 
could undergo an endoscopy with biopsies at one time and drink ALA only when the 
ratio would predict high PPIX levels, suggesting that this patient could be a candidate for 
ALA-PDT. Although the ratio, which we called the PDT power index was higher in BE and 
AC compared to SQ, this index was not found to predict PPIX accumulation in these tis-
sues under the conditions chosen in Chapter 4 (Hinnen et al., 2000a). However the high-
er PBG-D activities and lower PPIX precursor concentrations in AC and BE compared to 
SQ do suggest that the PDT power index might possibly have predicted PPIX levels at 
earlier time intervals (this was not studied) or with another ALA dose (Brand et al., 2000; 
Saidi et al., 2000) and that PPIX levels would have reached their maximum in BE at an 
earlier time interval after ALA ingestion than in SQ (studied in Chapter 5). 
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From the above it becomes clear that a simple relationship between enzyme activities 
and PPIX accumulation seems not very likely. This was supported by more recent stud-
ies, which show that PPIX accumulation also depends on many other variables like the 
temperature and pH in cells/tissues, cell cycle and differentiation, tissue oxygenation and 
the availability of iron (Gannon and Brown, 1999; Li et al., 1999; Moan et aI., 1999; Tan 
et al., 1997; Wyld et al., 1997; Wyld et al., 1998). 
fl. SELECTNE PPIX ACCUMULATION 
From fluorescence studies it appears that controversy exists as to whether the selectivity 
of ALA-induced PPIX accumulation lies in the difference between premalignant and nor-
mal epithelium or in the difference between epithelium and underlying muscle in the 
digestive tract (Barr et al., 1996; Bedwell et al., 1992; Regula et al., 1995; van den 
Boogert et al., 1999). In Chapter 4, we determined the intracellular concentrations of 
PPIX by biochemical extraction methods rather than fluorescence microscopy (Hinnen et 
al., 2000a). It was repeatedly (Chapter 4 and 5) found that there was no selectivity in 
PPIX accumulation, when using therapeutic doses of ALA, between Barrett's epithelium 
and surrounding normal squamous epithelium. At subtherapeutic doses of ALA (2 and 
10 mg/kg) preliminary data have shown a difference in PPIX fluorescence between 
Barrett's mucosa and normal squamous mucosa (Saidi et al., 2000). 
Transmural fluorescence studies of the oesophagus have shown a selectivity in PPIX accu-
mulation between mucosa and underlying muscle. Moreover, the effects of ALA-PDT 
have proven to be superficial, sparing the muscle layer, which leads to the conclusion that 
PPIX selectivity lies in the difference between mucosa and muscle but not between 
Barretl1s and squamous mucosa. 
Porphyrin extraction from Barrett's and normal squamous mucosa at different time inter-
vals after ALA ingestion (1-8 h after ALA ingestion, Chapter 5) have shown that PPIX lev-
els are significantly lower ',n Barrett's mucosa than in normal squamous mucosa. The only 
finding that might be of clinical use lies in the fact that maximum PPIX concentration 
occured significantly earlier after ALA ingestion in Barrett's oesophagus (4.6 h) than in the 
normal squamous mucosa (6.6 h). This leads to the conclusion that the most selective 
damage to Barrett's mucosa can be achieved early within the time window (4-5 h after 
ALA ingestion) of maximum PPIX levels in Barrett's mucosa. 
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III. PHOTOSENSITNITY: THE SIDE EFFEa 
Photosensitivity of all tissues, including skin and mucosa, is a side effect of the adminis-
tration of ALA to patients as porphyrins not only accumulate in cells of the target area 
but in all haem producing cells. 
The optimism about negligible photosensitivity of the skin after ALA administration (Barr 
et ai., 1996; Gossner et ai., 1998) was not confirmed by our studies (Chapter 4 and 5). 
In Chapter 4, 7 of 10 patients complained of some skin photosensitivity. In the study 
mentioned in Chapter 5, 35 percent of the patients developed painful erythema of their 
facial skin already during the first 9 h after administration of ALA despite being kept in 
a room with subdued light. In total, 77% of the patients developed skin photosensitivi-
ty. Additional preventive measures such as the application of sunscreen factor 70 did not 
prevent the symptoms of photosensitivity. 
Unwanted photosensitization tissue damage can be prevented in part by the use of acry-
late yellow filters as shown in Chapter 3. For the use of intra-operative PDT as an adju-
vant to curative tumour resection to destroy residual tumour the use of these filters is 
recommended. Perhaps the use of these filters in front of the windows could have reduced 
this side effect in Chapter 5. 
Compared to the morbidity of oesophagectomy or the side-effects of other cancer treat-
ments such as chemotherapy, the skin photosensitivity after ALA-PDT is acceptable. 
iV. OPTIMiZATiON OF ALA-PDT: TWO-PHASE ALA-PDT 
As mentioned before, PDT reqUires the presence of three components for its action, 
namely: a photosensitizer, light and oxygen. These three have to meet the following cri-
teria for any effect; (1) the concentration of the photosensitizer (PPIX) has to exceed a 
threshold (Hinnen et ai., 2000b), (2) a certain quantum of light energy -fluence rate and 
illumination time- has to be absorbed by photosensitizer molecules (PPIX) to create a 
minimum triplet status yield (see chapter 1, section lib, (Hinnen et ai., 2000b; linuma et 
ai., 1999)) and (3) tissue oxygenation should be optimal as hypoxia diminishes the PDT 
effect (Georgakoudi et ai., 1999). Despite this knowledge the effects of ALA-PDT in tis-
sues of patients are still limited to partial necrosis (Barr et ai., 1996; Fan et ai., 1996; 
Gossner et ai., 1998; Mlkvy et ai., 1995; Regula et ai., 1995). Optimization studies focus 
on the three components mentioned above (see Chapter 1). 
The idea of using light fractionation schedules to improve the outcome of PDT was 
prompted by the realization that rapid oxygen consumption during the photochemical 
process can lead to an oxygen deficit within a few seconds, especially in tumour areas 
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distant from the vessels, thereby protecting cells from further damage from PDT (Foster 
et ai., 1991 ; Mcilroy et ai., 1998). Moreover tumour vascular shutdown may also occur 
during ALA-PDT and this will further prevent an optimal PDT effect (Leveckis et ai., 
1995; Roberts et ai., 1994; van der Veen et ai., 1994). Recovery of vascular constriction 
during the dark period and as a result re-oxygenation of the tissues (Curnow et ai., 1999) 
will provide more oxygen to quench the triplet-state of PPIX and results in higher pro-
duction of oxygen radicals and ultimately in an increased PDT efficacy (Curnow et ai., 
1999; Hua et ai., 1995; Messmann et ai., 1995). From a theoretical study, it was shown 
that the optimal fractionation period depends only on the oxygen diffusion time (10 s) 
and it was speculated that long dark periods would probably be inefficient by allowing 
time for sublethal repair processes (Pogue and Hasan, 1997). At present, most light frac-
tionation schedules have been with equal times of light on and off, with an interval vary-
ing between 1 and 60 s, and the maximum tumoricidal effect has been observed with 
30-s and 60-s fractions (Foster et a/., 1991; linuma et ai., 1999). Previously, de Bruijn et 
ai. observed an improvement of the effect of ALA-PDT, in that the doubling time of the 
tumour volume of transplanted rat rabdomyosarcoma was prolonged using a light frac-
tionation time interval of 75 minutes (de Bruijn et ai., 1999). They proposed that new 
PPIX was formed during the interval of 75 min enhancing the effect of the second illu-
mination. Another way that proved succesful in our in vitro study described in Chapter 
7, was the use of a light fractionation schedule with a dark period of 3 hours (a two-
phase illumination scheme) as opposed to a continuous illumination schedule in EBV-
transformed Iymphoblastoid cells (Hinnen et ai., 2000c). Following the first illumination, 
cells were able to accumulate significantly more PPIX than their non-illuminated controls 
when continuously incubated with ALA. Two illuminations resulted in more cell death 
than one illumination. This is, at least in part, caused by the inhibitory effect of ALA-PDT 
on the haem biosynthetic enzyme ferrochelatase as we described in Chapter 6 (He et ai., 
1995; He et ai., 1993; Hinnen et ai., 2000b). So the mechanism of the re-appearance of 
PPIX fluorescence observed by van der Veen et ai. (van der Veen et ai., 1994) and the 
observed improvement of PDT after a second illumination by de Bruijn et ai. (de Bruijn 
et ai., 1999) may indeed be related to the decreased FC activity in cells after a single 
treatment. The decrease in FC activity caused by the initial course of ALA-PDT reduces 
the conversion of PPIX into haem, increases the accumulation of PPIX and provides an 
additional explanation for the increased PDT effect after two illuminations. In conclusion, 
increased PDT-sensitivity, which is the starting point for the concept of light fractionation 
schedules to enhance the ultimate outcome of PDT is not only determined by tissue 
reoxygenation but probably also by the renewed PPIX syntheSiS after ALA-PDT induced 
FC inhibition (Hinnen et ai., 2000b; Hinnen et ai., 2000c). Other factors that might play 
a role are the subcellular localization of PPIX and the cell cycle phase at the time of illu-
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mination. PPIX is synthesized in the mitochondrion, but diffuses to other cellular sites 
(Iinuma et al., 1994; Steinbach et al., 1995). The subcellular localization of PPIX at the 
time of PDT might therefore playa role in the effect of one or two illuminations. The 
metabolic activity of a cell varies with the phase of the cell cycle. Cells in certain phases 
of the cell cycle have been shown to produce different amounts of PPIX and their PDT 
sensitivity correlated with the PPIX concentration (Wyld et al., 1998). One should realise 
that besides the intracellular factors and vascular supply, other local tissue factors like the 
presence and action of neutrophils probably play an important role in the PDT effect as 
well (de Vree et al., 1996). 
Whether the clinical outcome of ALA-PDT will improve using long-term light fractiona-
tion remains uncertain. Only the study by Fan et al. demonstrated a benificial effect of 
long term light fractionation in ALA-PDT in patients with premalignant and malignant 
lesions of the oral cavity (Fan et al., 1996). Despite a light fractionation schedule, they 
observed partial necrosis in all cases, however their timing was not ideal. Considering the 
fractionated ALA doses that they used and the pharmacokinetics of ALA and PPIX that 
we studied in oesophageal mucosa (Chapter 5), PPIX levels where probably suboptimal 
at the time of treatment. 
V. FUTURE RESEARCH 
The basic concept of the approach described here is that the best way to prevent pro-
gression of Barrett's epithelium to oesophageal cancer is to selectively remove the 
Barrett's epithelium and, by suppresing reflux of (acid)stomach contents, allow the nor-
mal squamous epithelim to regrow. Unfortunately, support for this approach is at present 
largely theoretical or limited to shortterm clinical studies. Before this approach can be rec-
ommended for clinical practice it is obvious that many studies still need to be done. A few 
clinical studies of ALA-PDT for the treatment of Barrett's oesophagus, which are not well doc-
umented in terms of exact timing and fluence rates, have been reported (Barr et al., 1996; 
Gossner et al., 1998; Tan et al., 1999). Before performing large scale studies on ALA-PDT to 
remove Barrett's epithelium, further studies on the histological effects are needed. One pos-
sibility to gain insight in the extent of the histological effect of PDT is to subject patients who 
have to undergo an oesophagus resection because of the existence of an adenocarcinoma 
or high-grade dysplasia in Barrett's oesophagus to ALA-PDT a few days prior to the resec-
tion. 
In addition, the improved damaging effect of a second illumination found in cell lines 
need to be confirmed by studies in patients with Barrett's oesophagus, preferably in 
patients shortly before they undergo oesophagectomy. Pathogenetic studies on Barrett's 
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oesophagus will provide us with knowledge on how to optimize the treatment of 
Barrett's oesophagus. In addition, such studies can even provide us with insight in the 
possible prevention of Barrett's oesophagus or the development of adenocarcinoma with-
in it. 
As stated in the introduction, Barrett's oesophagus is almost certainly a consequence of 
chronic reflux of stomach contents into the oesophagus. Not only acid but also bile reflux 
is damaging to the squamous epithelium as is reviewed by Byrne et al. (Byrne and 
Attwood, 1999). The latter is often forgotten as is shown by the concept of medical anti-
reflux therapy with proton pump inhibitors. In general neither the length of the Barrett's 
segment nor the grade of dysplasia within this segment is altered by medical treatment. 
Proton pump inhibitors (PPI) are often prescribed for patients with Barrett's oesophagus 
as they control symptoms, and create an environment in which ulcers heal and stricture 
formation is prevented (Shepherd, 2000). Despite the fact thattreatment with PPI's does 
not result in total regression of Barrett's epithelium, partial regression has occasionally 
been demonstrated with prolonged PPI treatment (Peters et al., 1999). However, the 
most important question is not whether complete regression will result but whether neo-
plastic progress'lon will be stopped. 
Anti-reflux surgery such as Nissen fundoplication prevents both bile and acid reflux and 
may theoretically prevent the development of adenocarcinoma in Barrett's oesophagus. 
However in practice this therapy does also not seem to influence the incidence of carci-
noma in Barrett's oesophagus. This may be because that by the time of operation, molec-
ular and cellular events leading to the eventual development of malignancy have already 
occurred. Further studies are needed to investigate whether early Nissen fundoplication 
can prevent the development of adenocarcinoma within Barrett's oesophagus. However 
the very limited effects, if any, of anti-reflux treatment alone on replacement of Barrett's 
epithelium by squamous epithelium, suggest that removal of Barrett's epithelium will be 
an essential step in preventing adenocarcinoma of the lower oesophagus. It therefore 
seems highly worthwhile to continue to develop therapies such as PDT to safely remove 
Barrett's epithelium. Once a more consistently effective means of ablation has been 
defined, long-term studies in which PPI therapy alone or anti-reflux surgery alone is com-
pared with either ALA-PDT alone or a combination of ALA-PDT with PPI's or surgery, 
would be necessary to answer the question whether Barrett's oesophagus should be treat-
ed by photodynamic therapy at all. 
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The incidence of oesophageal adenocarcinoma is increasing more rapidly than that of any 
other cancer in the western world. Adenocarcinoma is assumed to arise in Barrett's 
oesophagus, a metaplastic epithelial transformation as a reaction to chronic gastro(duo-
denal)-oesophageal reflux. Despite excellent anti-reflux medication and modern anti-
reflux surgery, neither the length nor the grade of dysplasia of Barrett's oesophagus is 
influenced, so malignant transformation can still proceed. 
A promising non-invasive treatment of Barrett's oesophagus studied in this thesis is pho-
todynamic therapy (PDT). For its destructive effect, PDT requires a photoactive agent -
in our studies, protoporphyrin IX (PPIX) formed from administered 5-aminolaevulinic acid 
(ALA)-, light of an appropriate wavelength - 633 nm- and oxygen. To date results of clin-
ical trials are promising but more research needs to be performed before ALA-PDT can be 
used as a standard therapy. 
The studies in this thesis were set up to explore underlying mechanisms of ALA-induced 
PPIX accumulation in tissues of patients with Barrett's oesophagus. In addition in vitro 
studies were performed to find tools to optimize ALA-PDT and provide a basis for fur-
ther clinical studies. 
In chapter 1, the pathophysiology, diagnosis and management of Barrett's oesophagus 
are described. Barrett's oesophagus is a metaplastic lesion in the distal oesophagus. The 
diagnosis is based on histology of endoscopically derived biopsies. Barrett's oesophagus 
seems to result from chronic gastro(duodeno)oesophageal reflux and has the potential to 
undergo further changes. Barrett's oesophagus can lead to the development of adeno-
carcinoma of the oesophagus through a sequence of progression from metaplasia to low-
grade dysplasia, high-grade dysplasia and ultimately to invasive cancer. Although reflux is 
considered the major metaplasia-inducing factor, reducing acid exposure of the Barrett's 
segment does not influence the length nor the grade of dysplasia of Barrett's oesopha-
gus and malignant degeneration can still proceed. Patients with low-grade dysplasia may 
undergo regular endoscopies. The majority of patients with high-grade dysplasia are 
often subjected to a prophylactic oesophagectomy. A non-invasive endoscopic ablative 
therapy could be an alternative to surgical resection. 
The history of PDT dating from the end of the 19th century and its fundamentals are 
described. PDT requires the presence of a light sensitive compound (photosensitizer), 
light and oxygen. Absorption of light of an appropriate wavelength by the previously 
administered and accumulated photosensitizer leads to the formation of oxygen radicals, 
which oxidize cellular structures and ultimately lead to tissue destruction. 
5-Aminolaevulinic acid (ALA), a naturally occurring intermediary of the haem biosyn-
thetic pathway is a promising pro-drug for the photodynamiC treatment of Barrett's 
oesophagus. Exogenous administration of the pro-drug ALA leads to intracellular 
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accumulation of the photosensitizer protoporphyrin IX (PPIX). Clinical studies into ALA-
PDT in patients with Barrett's oesophagus showed promising results but also suggest that 
ALA-PDT needs to be improved. 
Chapter 2 describes the results of a study performed in 27 patients undergoing an 
oesophageal resection. Nine patients had a squamous cell carcinoma, 18 had an adeno-
carcinoma of the distal oesophagus and in nine of these patients Barrett's epithelium was 
present. Samples from histological proven Barrett's mucosa, squamous cell carcinoma and 
adenocarcinoma as well as normal gastric mucosa and normal squamous epithelium were 
taken immediately after the resection. The grade of tumour differentiation and the grade 
of dysplasia in Barrett's epithelium were determined. The activities of two haem biosyn-
thetic enzymes, porphobilinogen deaminase (PBG-D) and ferrrochelatase (FC) were meas-
ured. A PDT power index for ALA-induced porphyrin accumulation, the ratio between 
PBG-D to FC normalised for normal squamous epithelium of the oesophagus, was calcu-
lated to evaluate the intertissue variation in the ability to accumulate porphyrins. 
A twofold increase in PBG-D activity was found in Barrett's epithelium and adenocarci-
noma of the oesophagus compared with normal squamous epithelium. The increase in 
FC activity in these tissues was less marked than the increase in PBG-D activity, resulting 
in a significantly increased PDT power index in Barrett's oesophagus and adenocarcino-
ma compared with normal squamous epithelium. 
This biochemical study has characterized the enzymatic capacities of haem biosynthesis 
in normal, premalignant and malignant tissue ofthe human oesophagus and provides evi-
dence for selective accumulation of porphyrins after ALA administration. We suggested 
that the PDT power index might be a useful parameter for predicting the accumulation 
of porphyrins in tissues after ALA administration. Whether this will indeed be the case 
was studied in further studies described in chapter 4 and 5. 
Photosensitivity of all tissues, including skin and mucosa, is a side effect of the admin-
istration of ALA to patients as porphyrins not only accumulate in cells of the target area 
but in all haem-producing cells. Before subjecting photosensitized patients to the bright 
lights in the operating room, we performed the study described in chapter 3. Acrylate 
yellow filters could theoretically reduce unwanted tissue damage when photosensitised 
patients are subjected to operating lights. In this study, the spectral power distribution 
of the operating lights and light energy densities with and without acrylate yellow filters 
were measured. Subsequently, the effects of light exposure on the survival of a human 
hepatocellular carcinoma cell line and the photodamage induced in pig tissues after the 
administration of 5-aminlaevulinic acid were studied. The light energy density in the 
ultraviolet and blue region of the light spectrum emitted by the operating light was 
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reduced by up to 50 per cent by the acrylate yellow filter. The survival of photosensi-
tised cells was longer and photodamage induced in pig tissues was less when exposed 
to filtered light. It was therefore concluded that photodamage induced by operating 
lights could be reduced by filtering out ultraviolet and blue light by means of acrylate 
yellow filters. 
In chapter 4, 5 -Aminolaevulinic acid-induced porphyrin biosynthesis was studied in tis-
sues of 10 patients with Barrett's oesophagus (BE) and adenocarcinoma of the oeso-
phagus (AC) undergoing oesophagectomy at a mean time interval of 6.7 hours after 
the ingestion of ALA (60 mg/kg). In BE, AC, squamous epithelium (SO) and gastric 
cardia, - the activities of the haem biosynthetic enzymes, porphobilinogen deaminase 
(PBG-D) and ferrochelatase (FC) and the PDT power index - the ratio between PBG-D 
and FC in BE and AC in comparison with SO - were determined before ALA ingestion. 
Following ALA administration, ALA, porphobilinogen, uroporphyrin I and PPIX were 
determined in tissues and plasma. The PDT power index did not predict the level of 
intracellular accumulation of PPIX found at 6.7 hrs. In BE, there was no selectivity of 
PPIX accumulation compared to SO, whereas in half of patients with AC selectivity 
was found. Higher haem biosynthetic enzyme activities (i.e. PBG-D) and lower PPIX 
precursor concentrations were found in BE and AC compared to SO. We therefore 
speculated that it is possible that PPIX levels will peak at earlier time intervals in BE 
and AC compared to SO. 
In chapter 5 we investigated whether peak levels of PPIX actually occur at earlier time 
intervals after ALA ingestion in Barrett's oesophagus compared to normal oesophagus. 
Twenty six patients with BE were randomized to varying time intervals between ingest-
ing 60 mg/kg ALA and undergoing an endoscopy with biopsies of BE and normal 
oesophageal and gastric mucosa. At 1, 2, 7, 8 and 24 hrs, two patients at each time and 
at 3, 4, 5 and 6 hrs after ALA ingestion, 4 patients at each time were included. ALA, 
porphyrin intermediates and PPIX were determined in the biopsy samples and also in 
plasma samples derived at various time intervals after ALA administration. 
The maximum concentration of PPIX was found significantly earlier in BE (4.6 ± 0.5 hrs) 
than in SO (6.6 ± 2.2 hrs) (p< 0.05). Concentrations of PPIX were higher in SO than in 
BE especially at longer time intervals after ALA ingestion. In addition, tissue ALA con-
centrations were found to be 20-fold higher than the plasma concentrations at 1 hour 
after ALA ingestion, suggesting uptake from the oesophageal lumen. Skin photosensitiv-
ity is short-lasting but was often debilitating. These results provide a biological rationale 
for the use of ALA-PDT for the treatment of BE at 4-5 hrs after ALA ingestion (60 mg/kg) 
and for the local application of ALA in the oesophagus. 
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Chapter 6 describes an in vitro study in which the effect of ALA-PDT, using UV light and 
633 nm laser light, on the activities of two haem biosynthetic enzymes porphobilinogen 
deaminase and ferrochelatase was studied in human EBV-transformed Iymphoblastoid 
cell lines as a model of human tumour cells. Ferrochelatase activity was significantly 
inhibited by ALA-PDT, whereas the porphobilinogen deaminase activity remained 
unchanged. The extent of ferrochelatase inhibition was related both to the intracellular 
protoporphyrin IX concentration and to the time of UV light exposure. ALA-PDT there-
fore causes a relative block in haem biosynthesis by inhibiting ferrochelatase. We hypoth-
esised that a short period of pre-illumination of ALA-treated porphyrin-loaded tissues 
might enhance porphyrin accumulation and a second illumination might result in a more 
pronounced ALA-PDT effect. 
The hypothesis at the end of chapter 6 was explored in vitro for its credibility in 
Chapter 7. To examine the effect of ALA-PDT on PPIX accumulation and the effect of 
one or two laser treatments (two-phase ALA-PDT) on cell survival, we used EBV-trans-
formed Iymphoblastoid cells as a model of human tumour cells. ALA-treated cells were 
illuminated ones or twice with 633 nm laser light (100 mW Icm2 ) or kept in the dark for 
the same time period. At selected times, the porphyrin concentrations and protein con-
tents as a measure of cell death were determined. Porphyrin biosynthesis remained intact 
in EBV-transformed Iymphoblastoid cells after a first episode of ALA-PDT. Following the 
first illumination, cells were able to accumulate significantly more PPIX than their non-
illuminated controls. Two illuminations resulted in more cell death than one illumination. 
A two-phase illumination scheme may improve the clinical outcome of ALA-PDT. 
In Chapter 8 the findings described in this thesis are discussed. 
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De incidentie van slokdarmkanker (m.n het adenocarcinoom van de slokdarm) neemt 
sneller toe dan van enig andere vorm van kanker in de Westerse wereld. 
Adenocarcinoom ontstaat in een Barrett slokdarm, een metaplastische verandering in het 
onderste deel van de slokdarm als reactie op chronische reflux van maag- en darmsap-
pen. Anti-reflux medicamenten en moderne anti-reflux chirurgie beinvloeden noch de 
lengte van het Barrett segment noch de graad van dysplasie en kwaadaardige ontaarding 
wordt niet voork6men. 
Een veelbelovende niet-invasieve behandelingsmethode voor Barrett slokdarm, die in dit 
proefschrift wordt bestudeerd, is fotodynamische therapie (PDT). Voor een weefselbe-
schadigend effect van PDT zijn de volgende factoren noodzakelijk: een lichtgevoelige stof 
-in onze studies protoporfyrine IX (PPIX) gevormd uit toegediend 5-aminolevuline zuur 
(ALA)- , licht van een specifieke golflengte -633 nm- en zuurstof. 
De resultaten van de klinische studies, die tot nu toe zijn verricht, zijn veelbelovend. Het 
is echter noodzakelijk verder onderzoek te verrichten alvorens ALA-PDT standaard in de 
klinische praktijk kan worden toegepast. 
De studies in dit proefschrift zijn verricht om de onderliggende mechanismen van ALA-
geinduceeerde stapeling van PPIX in weefsels van patienten met Barrett slokdarm te 
bestuderen. Daarnaast zijn in vitro studies verricht om ALA-PDT verder te optimaliseren. 
In hoofdstuk 1 werd de pathofysiologie, de diagnostiek en de behandeling van Barrett 
slokdarm beschreven. Barrett slokdarm is een metaplastische verandering in het distale 
deel van de slokdarm. De diagnose is gebaseerd op de histologische diagnose in biopten 
die verkregen zijn d.m.v. endoscopisch onderzoek. Barrett slokdarm lijkt het resultaat te 
zijn van chronische reflux van maag- en darmsappen en heeft de potentie verdere ver-
anderingen te ondergaan, die volgens de sequentie metaplasie, laaggradige dysplasie en 
hooggradige dysplasie kunnen leiden tot de vorming van een invasief adenocarcinoom. 
Hoewel reflux de belangrijkste metaplasie-inducerende faktor is, lijkt de reductie van zuur-
expositie in de Barrett slokdarm, noch de lengte van de Barrett slokdarm, noch de gra-
dering van dysplasie te beinvloeden en kan een kwaadaardige verandering optreden. 
Patienten met laaggradige dysplasie ondergaan periodieke endoscopische controles. Het 
merendeel van de patienten met hooggradige dysplasie ondergaat momenteel een pre-
ventieve slokdarmresectie. Een niet-invasieve endoscopische therapie ter verwijdering van 
het Barrett slijmvlies zou een klinisch significant alternatief voor chirurgie kunnen zijn. 
Voor een effect vereist PDT de aanwezigheid van een lichtgevoelige stof ("fotosensiti-
ser"), licht en zuurstof. Absorptie van licht van een specifieke golflengte leidt tot de vor-
ming van zuurstofradicalen, welke de oxidatie van allerlei celstucturen veroorzaken en lei-
den tot weefseldestructie. 
5-Aminolevuline zuur (ALA), een natuurlijk voorkomende intermediair van de heemsyn-
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these is een veelbelovende stof voor de fotodynamische behandeling van de Barrett slok-
darm. Toediening van ALA leidt tot intracellulaire stapeling van de "fotosensitiser" pro-
toporfyrine IX (PPIX). De resultaten van klinische studies naar de toepassing van ALA-
PDT voor de behandeling van patienten met Barrett slokdarm zijn veelbelovend, maar 
suggereren tevens dat ALA-PDT verder verbeterd dient te worden. 
In hoofdstuk 2 werden de resultaten beschreven van een studie, die verricht is bij 27 patien-
ten die een slokdarmresectie ondergingen. Negen patienten hadden een plaveiselcelcarci-
noom van de slokdarm, 18 hadden een adenocarcinoom van de slokdarm en bij 9 van deze 
laatste groep patienten was tevens Barrett slijmvlies aanwezig. Biopten werden direct na de 
resectie genomen uit histologisch bewezen Barrett slijmvlies, plaveiselcelcarcinoom en ade-
nocarcinoom alsmede van normaal maag- en slokdarmslijmvlies. De differentiatiegraad van 
de tumor en de graad van dysplasie van het Barrett slijmvlies werden microscopisch vast-
gesteld. Tevens werden de activiteiten van twee enzymen van de heemsynthese, nl. porfo-
bilinogeen deaminase (PBG-D) en ferrochelatase (FC) gemeten. De "PDT power index" voor 
ALA-geinduceerde porfyrine stapeling, dat is de ratio tussen PBG-D en Fe genormaliseerd 
voar narmaal slokdarmslijmvlies, werd berekend in bovengenoemde weefsels ter evaluatie 
van de variatie in de mate waarin deze weefsels porfyrines stapelen na ALA toediening. 
Een tweevoudige stijging van de activiteit van PBG-D werd gevonden in Barrett slijmvlies en 
in adenocarcinoom vergeleken met normaal slokdarm slijmvlies. De toename van de activi-
teit van FC was minder uitgesproken dan die van PBG-D wat resulteerde in een significant 
verhoogde "PDT power index" in Barrett slokdarm en adenocarcinoom van de slokdarm ver-
geleken met normaal slokdarmslijmvlies. 
Deze biochemische studie karakteriseerde de enzymatische capaciteit van de heemsynthese 
in normaal, premaligne en maligne weefsel van de humane slokdarm en leverde aanwijzi-
gen voar een selectieve stapeling van porfyrines na ALA toediening. Op grand van deze 
studie was onze hypothese dat de "PDT power index" een waardevolle parameter zou kun-
nen zijn voor het voorspellen van de stapeling van porfyrines in weefsels na ALA toedie-
ning. Of dit inderdaad zo is, werd bestudeerd en beschreven in de hoofdstukken 4 en 5. 
Lichtgevoeligheid van aile weefsels, inclusief huid en slijmvliezen, is een complicatie van 
het toedienen van ALA aan patienten omdat porfyrines niet aileen in het te behandelen 
weefsel maar in aile heemproducerende cellen stapelen. 
Voordat de lichtgevoelige patienten werden blootgesteld aan het felle licht van de ope-
ratielampen tijdens een slokdarmresectie, zoals noodzakelijk was in de studie genoemd 
in hoofstuk 4, werd een studie verricht die beschreven is in hoofdstuk 3. Theoretisch zou-
den acrylaat geelfilters ongewenste weefselschade kunnen vermin deren, die optreedt als 
lichtgevoelige patienten worden blootgesteld aan het licht van operatielampen. In deze 
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studie werden het lichtspectrum en de lichtenergie die operatielampen uitstralen met en 
zonder geelfilter gemeten. Vervolgens werd het effect van de belichting op de overleving 
van een humane leverkankerceliijn en de door licht geinduceerde schade aan varkens-
weefsels na het toedienen van ALA bestudeerd. De hoeveelheid lichtenergie in het ultra-
violette en blauwe deel van het lichtspectrum van de operatie lamp werd tot 50 procent 
gereduceerd door het acrylaat geelfilter. De overleving van lichtgevoelige celien was lan-
ger en de schade aan varkensweefsels was minder uitgesproken wanneer deze waren 
blootgesteld aan gefilterd licht. Op grond van deze studie werd geconcludeerd dat de 
door operatielampen geinduceerde weefselschade kan worden verminderd door ultravio-
let en blauw licht uit het lichtspectrum te filteren middels een acrylaat geelfilter. 
In hoofdstuk 4 werd de door 5-aminolevuline zuur geinduceerde porfyrine synthese 
bestudeerd in weefsels van 10 patienten met een Barrett slokdarm (BE) en adenocarci-
noom van de slokdarm (AC), die een slokdarm resectie ondergingen op een gemiddeld 
tijdtip van 6.7 uur na het drinken van ALA (60 mg/kg). In BE, AC, plaveiselepitheel (SQ) 
en maagcardia werden de activiteiten van de heemsynthese enzymen porfobilinogeen 
deaminase (PBG-D) en ferrachelatase (FC) en de "PDT power index" -De ratio tussen PBG-
D en FC in BE en AC in vergelijking met SQ- voor het toedienen van ALA bepaald. Na 
de toediening van ALA werden ALA, porfobilinogeen, uraporfyrine I en PPIX bepaald in 
bovengenoemde weefsels en in plasma. De "PDT power index" bleek geen voorspelien-
de waarde te hebben voor de concentratie van gestapeld PPIX op het tijdstip van 6.7 uur 
na toediening van ALA. Er was tevens geen selectieve stapeling van PPIX in BE vergele-
ken met SQ, in tegensteliing tot AC, waar in de he 1ft van de gevalien wei selectiviteit 
werd vastgesteld. In BE en AC werden verhoogde enzymactiviteiten (vooral PBG-D) en 
verlaagde PPIX voorloper moleculen gevonden in vergelijking met SQ. Op grand van 
deze studie speculeerden wij dat het mogelijk is dat maximum PPIX concentraties op een 
eerder tijdstip na het toedienen van ALA kunnen worden bereikt in BE en AC in vergelij-
king met SQ. 
In hoofstuk 5 werd onderzocht of de maximum PPIX concentraties inderdaad op een eer-
der tijdstip na het toedienen van ALA worden bereikt in BE in vergelijking met SQ. 
Zesentwintig patienten met een Barrett slokdarm werden gerandomiseerd naar verschil-
lende tijdsintervalien tussen het drinken van ALA (60 mg/kg) en het ondergaan van een 
endoscopisch onderzoek met afname van biopten uit BE en normaal slokdarm- en maag-
slijmvlies. Op 1, 2, 7. 8 en 24 uur werden 2 patienten op ieder tijdstip en op 3, 4, 5, 6 
uur werden 4 patienten op ieder tijdstip na het toedienen van ALA geincludeerd. ALA, 
porfyrine intermediairen en PPIX werden bepaald in biopten alsmede in plasma monsters 
afgenomen op verschiliende tijden na ALA toediening. 
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De maximum concentratie van PPIX werd significant eerder gevonden in BE (4.6 ± 0.5 
uur) dan in SO (6.6 ± 2.2 uur) (p< 0.05). De concentraties van PPIX waren hoger in SO 
dan in BE, vooral op latere tijdstippen na ALA toediening. Daarnaast bleken de weefsel 
ALA concentraties op 1 uur na ALA toediening 20 maal hoger dan de concentraties in 
plasma, wat ALA opname vanuit het slokdarmlumen in slokdarmcellen suggereert. 
Lichtgevoeligheid van de huid bleek kortdurend aanwezig maar werd vaak als zeer belas-
tend ervaren. Deze resultaten verschaffen een biologische onderbouwing voor het 
gebruik van ALA-PDT voor de behandeling van BE op 4-5 uur na het toedienen van ALA 
(60 mg/kg) alsmede voor de lokale toepassing van ALA in de slokdarm. 
In hoofdstuk 6 werd een in vitro studie beschreven waarin het effect van ALA-PDT met 
ultraviolet (UV) licht en 633 nm laser Iicht op de activiteiten van de twee heemsynthese 
enzymen, porfobilinogeen deaminase en ferrochelatase werd onderzocht in humane Epstein 
Barr Virus (EBV)-getransformeerde Iymfoblastoide cellijnen, welke gebruikt werden als een 
model voor humane tumorcellen. De activiteit van ferrochelatase werd significant geremd 
door ALA-PDT, terwijl de activiteit van porfobilinogeen deaminase niet veranderde. Er was 
een relatie tussen de mate van ferrochelatase activiteit remming en de concentratie van 
PPIX alsook de duur van de belichting met UV Iicht. ALA-PDT veroorzaakte dus een rela-
tieve blokkade in de heem synthese door de remming van ferrochelatase. Op grond van 
deze resultaten was onze hypothese dat een korte v66rbelichting van weefsel, dat na ALA-
toediening porfyrines heeft gestapeld, de verdere stapeling van porfyrines zal bevorderen 
en een daaropvolgende tweede belichting zal resulteren in een optimaler ALA-PDT resultaat. 
De hypothese opgeworpen aan het einde van hoofdstuk 6 werd getest in hoofstuk 7. Om 
het effect van ALA-PDT op de stapeling van PPIX en het effect van een of twee laserbe-
handelingen (twee-fase ALA-PDT) op de overleving van cellen te bestuderen, werden EBV-
getransformeerde Iymphoblastoide cellen gebruikt als een model voor humane tumorcel-
len. Cellen die met ALA behandeld waren, werden een of twee maal belicht met 633 nm 
laser licht of bleven gedurende een zelfde tijdsperiode in het donker. Op geselecteerde tijd-
stippen werden de porfyrine concentraties en de eiwit gehalten, als maat voor celdood, 
bepaald. De porfyrine synthese bleef intact na de eerste belichting. Tevens stapelden de 
belichte cellen meer PPIX dan hun niet-belichte controles. Twee belichtingen resulteerden 
in meer celdood dan een enkele belichting. Aan het einde van dit hoofdstuk speculeerden 
wij dat een belichtings schema met twee belichtingen de klinische resultaten van ALA-PDT 
wellicht zouden kunnen verbeteren in vergelijking met slechts een enkele belichting. 
In hoofdstuk 8 worden de bevindingen, beschreven in dit proefschrift, bediscussierd. 
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Chapter 11 
List of Abbreviations 
AC 
ALA 
ALA-S 
ALAT 
ASAT 
BE 
DMSO 
EBV 
Fe 
FCS 
F.U. 
GC 
HGD 
HPlC 
Hp 
HpD 
KTP 
lGD 
ND 
Nd-Yag 
PSG 
PBG-D 
PDT 
PEB 
PPIX 
SD 
SEM 
SQ 
UEB 
URO 
URO-S 
UV 
adenocarcinoma 
5-aminolaevulinic acid 
5-aminolaevulinic acid synthase 
alanine aminotransferase 
aspartate aminotransferase 
Barrett's esophagus 
dimethylsulfoxide 
Epstein Barr virus 
ferrochelatase 
fetal calf serum 
fluorescence units 
gastric cardia 
high-grade dysplasia 
high performance liquid chromatography 
haematoporphyrin 
haematoporphyrin derivative 
potassium titanium phosphate 
low-grade dysplasia 
no dysplasia 
neodymium:yttrium-aluminium-garnet 
porphobilinogen 
porphobilinogen deaminase 
photodynamic therapy 
protoporphyrin IX extraction buffer 
protoporphyrin IX 
standard deviation 
standard error of the mean 
squamous epithelium 
uroporphyrinogen I extraction buffer 
uroporphyrinogen 
uroporphyrinogen III synthase 
ultraviolet 
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